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In 1995, the U.S. Public Health Service (USPHS) and the Infectious Diseases Society of America (IDSA) developed 
guidelines for preventing opportunistic infections (OIs) in persons infected with human immunodeficiency virus (HIV) 
(1-3). These guidelines, written for health-care providers and patients, were revised in 1997 (4) and again in 1999 (5), 
and have been published in the MMWR (1,4,5), Clinical Infectious Diseases (2,6,7), the Annals of Internal Medicine 
(3,8), the American Family Physician (9,10), and Pediatrics (11); accompanying editorials have appeared in JAMA 
(12,13). Response to these guidelines (e.g., the many requests for reprints, numerous web site contacts, and observations 
from health-care providers) suggests they have served as a valuable reference for HIV care providers. Because the 1995, 
1997, and 1999 guidelines included ratings indicating the strength of each recommendation and the quality of supporting 
evidence, readers have been able to assess the relative importance of each recommendation. 
Since AIDS was first recognized 20 years ago, remarkable progress has been made in improving the quality and duration 
of life of HIV-infected persons in the industrialized world. During the first decade of the epidemic, this improvement 
occurred because of better recognition of opportunistic disease processes, better therapy for acute and chronic 
complications, and the introduction of chemoprophylaxis against important opportunistic pathogens. The second decade 
of the epidemic has witnessed extraordinary progress in developing highly active antiretroviral therapies (HAART) as 
well as continuing progress in preventing and treating individual OIs. HAART has reduced the incidence of OIs and 
extended life substantially (14-16). HAART is the most effective approach to preventing OIs and should be considered 
for all HIV-infected persons who qualify for such therapy (14-16). However, some patients are not ready or able to take 
HAART, and others have tried HAART regimens, but therapy has failed. Such patients will benefit from prophylaxis 
against OIs (15). In addition, prophylaxis against specific OIs continues to provide survival benefits even among persons 
who are receiving HAART (15). 
Since HAART was introduced in the United States in 1995, it has become increasingly clear that 
chemoprophylaxis for opportunistic infection need not necessarily be life-long. Antiretroviral therapy can restore 
immune function. The period of susceptibility to opportunistic processes continues to be accurately indicated by 
the CD4+ T-lymphocyte count for patients who are receiving HAART. Thus, a strategy of stopping primary or 
secondary prophylaxis for certain patients whose immunity has improved as a consequence of HAART seems 
logical. Stopping prophylactic regimens can simplify treatment, reduce toxicity and drug interactions, lower cost 
of care, and potentially facilitate adherence to antiretroviral regimens. 
In 1999, the USPHS/IDSA guidelines suggested that it may be safe to stop primary or secondary prophylaxis for 
some (but not all) pathogens if HAART has led to an increase in CD4+ T-lymphocyte counts above specified 
threshold levels. Recommendations were made for only those pathogens for which adequate clinical data were 
available. Data generated since 1999 continue to support these recommendations and allow additional 
recommendations to be made concerning the safety of stopping primary or secondary prophylaxis for other 
pathogens. 
For recommendations on discontinuation of chemoprophylaxis, readers will note that criteria vary by such 
factors as duration of CD4+ T lymphocyte count increase, and, in the case of secondary prophylaxis, duration of 
treatment of the initial episode of disease. These differences reflect the criteria used in specific studies. 
Therefore, some inconsistency in the format of these criteria is unavoidable. 
Although considerable data are now available concerning discontinuing primary and secondary OI prophylaxis, 
essentially no data are available regarding restarting prophylaxis when the CD4+ lymphocyte count decreases 
again to levels at which the patient is likely to again be at risk for OI. For primary prophylaxis, whether to use 
the same threshold at which prophylaxis may be stopped (derived from data in studies addressing prophylaxis 
discontinuation), or to use the threshold below which initial prophylaxis is recommended, is unknown. Therefore 
in this revision of the guidelines, in some cases ranges are provided for restarting primary or secondary 
prophylaxis For prophylaxis against Pneumocystis carinii pneumonia (PCP), the suggested threshold for 
restarting both primary and secondary prophylaxis is 200 cells/µL. For all these recommendations, the Roman 
numeral ratings reflect the lack of data available to assist in making these decisions (see description of rating 
system below). 
During the development of these revised guidelines, working group members reviewed published manuscripts as well as 
abstracts and material presented at professional meetings. A series of teleconferences were held to develop the 
revisions. In this revision, information and recommendations which are new since the 1999 publication are 










Major Changes in these Recommendations
 
Major changes in the guidelines since 1999 include:
 
Higher level ratings have been provided for discontinuing primary prophylaxis for PCP and MAC when 
CD4+ T lymphocytes have increased to >200 cells/µL and >100 cells/µL, respectively, for 3 months in 
response to HAART (AI), and a new recommendation to discontinue primary toxoplasma prophylaxis 
has been provided when the CD4+ T lymphocyte count has increased to >200 cells/µL for 3 months (AI). 
•	 Secondary PCP prophylaxis should be discontinued in patients whose CD4+ counts have increased to > 
200 cells/µL for 3 months as a consequence of HAART (BII). 
• Secondary prophylaxis for disseminated MAC may be discontinued in patients with a sustained (e.g., 6 
months) increase in CD4+ count to >100cells/µL in response to HAART if they have completed 12 months 
of MAC therapy and have no symptoms or signs attributable to MAC (CIII). 
•	 Secondary prophylaxis for toxoplasmosis and cryptococcosis may be discontinued in patients with a 
sustained increase in CD4+ counts (e.g. 6 months) to >200 cells/µL and >100-200cells/µL respectively, 
in response to HAART if they have completed their initial therapy and have no symptoms or signs 
attributable to these pathogens (CIII). 
•	 The importance of screening all HIV-infected individuals for hepatitis C virus (HCV) is emphasized 
(BIII). 
•	 Additional information about transmission of human herpesvirus 8 infection (HHV-8) is provided. 
•	 New information on drug interactions is provided, especially with regard to rifamycins and antiretroviral 
drugs. 
•	 Revised recommendations for immunization of HIV exposed/infected adults and children are provided. 
How to Use the Information in This Report 
For each of the 19 diseases covered in this report, specific recommendations are provided that address a) prevention of 
exposure to the opportunistic pathogen, b) prevention of the first episode of disease, and c) prevention of disease 
recurrence. Recommendations are rated by a revised version of the IDSA rating system (17). In this system, the letters A 
through E signify the strength of the recommendation for or against a preventive measure, and Roman numerals I 
through III indicate the quality of evidence supporting the recommendation (see Box). 
System used to rate the strength of recommendations and quality of supporting evidence 
Rating Strength of the Recommendation 
A Both strong evidence for efficacy and substantial clinical benefit support recommendation for 
use. Should always be offered. 
B Moderate evidence for efficacy -- or strong evidence for efficacy but only limited clinical 
benefit -- supports recommendation for use. Should generally be offered. 
C Evidence for efficacy is insufficient to support a recommendation for or against use. Or 
evidence for efficacy might not outweigh adverse consequences (e.g., drug toxicity, drug 
interactions) or cost of the chemoprophylaxis or alternative approaches. Optional. 
D Moderate evidence for lack of efficacy or for adverse outcome supports a recommendation 
against use. Should generally not be offered. 
E Good evidence for lack of efficacy or for adverse outcome supports a recommendation 
against use. Should never be offered. 
Quality of evidence supporting the recommendation 
I Evidence from at least one properly randomized, controlled trial. 
II Evidence from at least one well-designed clinical trial without randomization, from cohort or 
case-controlled analytic studies (preferably from more than one center), or from multiple 
time-series studies. Or dramatic results from uncontrolled experiments. 
III Evidence from opinions of respected authorities based on clinical experience, descriptive 
studies, or reports of expert committees. 
Because of their length and complexity, the tables in this report are grouped together, following the references. The 




infected adults and adolescents (Table 1); dosages for prophylaxis to prevent recurrence of opportunistic disease in HIV-
infected adults and adolescents (Table 2); effects of food on drugs used to treat OIs (Table 3); effects of medications on 
drugs used to treat OIs (Table 4); effects of OI medications on drugs commonly administered to HIV-infected persons 
(Table 5); adverse effects of drugs used to manage HIV infection (Table 6); dosages of drugs for prevention of OIs for 
persons with renal insufficiency (Table 7); costs of agents recommended for the prevention of OIs in adults with HIV 
infection (Table 8); immunologic categories for HIV-infected children (Table 9); immunization schedule for HIV-
infected children (Table 10); dosages for prophylaxis to prevent first 
episode of opportunistic disease in HIV-infected infants and children (Table 11); dosages for prophylaxis to prevent 
recurrence of opportunistic disease in HIV-infected infants and children (Table 12); and criteria for discontinuing and 
restarting OI prophylaxis for adult patients with HIV infection (Table 13). Recommendations advising patients how to 
prevent exposure to opportunistic pathogens appear in the appendix at the end of this report. 
This report is oriented toward the prevention of specific opportunistic infections in HIV-infected persons in the United 
States and other industrialized countries. Recommendations for use of HAART, which is designed to prevent 
immunologic deterioration, to restore immune function and delay the need for many of the chemoprophylactic strategies 
described in this report, were originally published elsewhere (14) and are updated regularly (www.hivatis.org) (16). 
Pamphlets for patients regarding prevention of opportunistic infections can be obtained from the HIV/AIDS 
Treatment Information Service (ATIS) by calling (800) 448-0440, (301) 519-0459 (international), or (888) 480-
3739 (TTY). They also can be accessed on both the CDC and HIVATIS websites (www.cdc.gov/hiv/pubs/brochure.htm and 
www.hivatis.org). 
New data on prevention of OIs in HIV-infected persons are emerging, and randomized controlled trials addressing some 
unresolved issues in OI prophylaxis are ongoing. The OI Working Group review emerging data routinely and will update 
these guidelines on a regular basis. 
DISEASE-SPECIFIC RECOMMENDATIONS 
Pneumocystis carinii Pneumonia 
Prevention of Exposure 
1. Although some authorities recommend that persons with human immunodeficiency virus (HIV) infection who are at 
risk for P. carinii pneumonia (PCP) not share a hospital room with a patient who has PCP, data are insufficient to support 
this recommendation as standard practice (CIII). 
Prevention of Disease 
Initiation of Primary Prophylaxis 
2. Adults and adolescents who have HIV infection (including pregnant women and those on HAART) should receive 
chemoprophylaxis against PCP if they have a CD4+ T-lymphocyte count of less than 200/µL (AI) or a history of 
oropharyngeal candidiasis (AII) (18-20). Persons who have a CD4+ T-lymphocyte percentage of less than 14% or 
history of an acquired immunodeficiency syndrome (AIDS)-defining illness but do not otherwise qualify should be 
considered for prophylaxis (BII) (18-20). When monitoring the CD4+ T-lymphocyte count at least every 3 months is not 
possible, initiation of chemoprophylaxis at a CD4+ T-lymphocyte count of greater than 200 but less than 250 cells/µL 
also should be considered (BII) (19). 
3. Trimethoprim-sulfamethoxazole (TMP-SMZ) is the recommended prophylactic agent (AI) (20-23). One double-
strength tablet per day is the preferred regimen (AI) (23). However, one single-strength tablet per day (23) is also 
effective and might be better tolerated than one double strength tablet per day (AI). One double-strength tablet three 
times per week is also effective (BI) (24). TMP-SMZ at a dose of one double-strength tablet per day confers cross-
protection against toxoplasmosis (25) and some common respiratory bacterial infections (21,26) Lower doses of TMP-
SMZ also might confer such protection. For patients who have an adverse reaction that is not life-threatening, treatment 
with TMP-SMZ should be continued if clinically feasible; for those who have discontinued such therapy because of an 
adverse reaction, reinstitution of TMP-SMZ should be strongly considered after the adverse event has resolved (AII). 
Patients who have experienced adverse events, especially fever and rash, might better tolerate reintroduction of the drug 
with a gradual increase in dose (desensitization) as per published regimens (BI) (27,28) or reintroduction of TMP-SMZ 
at a reduced dose or frequency (CIII); up to 70% of patients can tolerate such reinstitution of therapy (26). 
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4. If TMP-SMZ cannot be tolerated, prophylactic regimens that can be recommended as alternatives include dapsone 
(BI), (21) dapsone plus pyrimethamine plus leucovorin (BI) (29,30), aerosolized pentamidine administered by the 
Respirgard IITM nebulizer (Marquest, Englewood, Colorado) (BI), (22) and atovaquone (BI) (31,32). Atovaquone 
appears to be as effective as aerosolized pentamidine (31) or dapsone (BI) (32) but is substantially more expensive than 
the other regimens. For patients seropositive for Toxoplasma gondii who cannot tolerate TMP-SMZ, recommended 
alternatives to TMP-SMZ for prophylaxis against both PCP and toxoplasmosis include dapsone plus pyrimethamine (BI) 
(29,30) or atovaquone with or without pyrimethamine (CIII). The following regimens generally cannot be recommended 
as alternatives because data regarding their efficacy for PCP prophylaxis are insufficient for a firm recommendation: 
aerosolized pentamidine administered by other nebulization devices, intermittently administered parenteral pentamidine, 
oral pyrimethamine plus sulfadoxine, oral clindamycin plus primaquine, and intravenous trimetrexate. However, 
clinicians may consider using these agents in unusual situations in which the recommended agents cannot be 
administered (CIII). 
Discontinuation of Primary Prophylaxis 
5. Primary pneumocystis prophylaxis should be discontinued in adult and adolescent patients who have 
responded to HAART with an increase in CD4+ T lymphocyte counts to >200 cells/µL for at least 3 months (AI). 
In observational and randomized studies supporting this recommendation, most patients were taking 
antiretroviral regimens that included a protease inhibitor and most had a CD4+ T cell count greater than 200 
cells/µL for at least 3 months before discontinuation of PCP prophylaxis (33-41). The median CD4+ lymphocyte 
count at the time prophylaxis was discontinued was >300 cells/µL, and many patients had a sustained suppression 
of HIV plasma RNA levels below detection limits of the assay employed. Median follow-up ranged from 6-16 
months. 
Discontinuation of primary prophylaxis in these patients is recommended not only because prophylaxis appears 
to add very little to disease prevention (for PCP, toxoplasmosis, or bacterial infections), but also because 
discontinuation of drug reduces pill burden, the potential for drug toxicity, drug interactions, selection of drug-
resistant pathogens, and cost. 
Restarting Primary Prophylaxis 
6. Prophylaxis should be reintroduced if the CD4+ T lymphocyte count decreases to <200 cells/µL (AIII). 
Prevention of Recurrence
 7. Patients who have a history of PCP should be administered chemoprophylaxis (i.e., 
secondary prophylaxis or chronic maintenance therapy) with the regimens listed in Table 2 for life (AI) unless 
immune reconstitution occurs as a consequence of HAART (see Recommendation #8 below). 
Discontinuation of Secondary Prophylaxis (Chronic Maintenance Therapy) 
8. Secondary prophylaxis should be discontinued for adult and adolescent patients whose CD4+ T cell count has 
increased from <200 cells µL to >200 cells/µL for at least 3 months due to HAART (BII). Reports from 
observational studies (37,41,42) and from a randomized trial (39), as well as a combined analysis of 8 European 
cohorts being followed prospectively, (43) support this recommendation. In these studies, patients had responded 
to HAART with an increase in CD4+ T-lymphocyte count to >200 cells/µL for at least 3 months. Most patients 
were taking protease inhibitor-containing regimens. The median CD4+ T-lymphocyte count at the time 
prophylaxis was discontinued was > 300 cells/µL. Most patients had sustained suppression of HIV plasma HIV 
RNA levels below the detection limits of the assay employed; the longest follow-up was 13 months. If the episode 
of PCP occurred at a CD4+ T lymphocyte count >200 cells/µL, it is probably prudent to continue PCP 
prophylaxis for life regardless of how high the CD4+ T lymphocyte count rises as a consequence of HAART 
(CIII). 
Discontinuation of secondary prophylaxis for patients is recommended not only because prophylaxis appears to 
add very little to disease prevention (for PCP, toxoplasmosis, or bacterial infections), but also because 
discontinuation of drug reduces pill burden, the potential for drug toxicity, drug interactions, and selection of 
drug resistant pathogens, and cost. 
Restarting Secondary Prophylaxis 
Prophylaxis should be reintroduced if the CD4+ T lymphocyte count decreases to < 200 cells/µL (AIII), or if PCP 






10. Children born to HIV-infected mothers should be administered prophylaxis with TMP-SMZ beginning at 4-6 weeks 
of age (44)(AII). Prophylaxis should be discontinued for children who are subsequently found not to be infected with 
HIV. HIV-infected children and children whose infection status remains unknown should continue to receive 
prophylaxis for the first year of life. The need for subsequent prophylaxis should be determined on the basis of age-
specific CD4+ T-lymphocyte count thresholds (Table 11) (AII). The safety of discontinuing prophylaxis in HIV-infected 
children receiving HAART has not been studied extensively. 
11. Children who have a history of PCP should be administered lifelong chemoprophylaxis to prevent recurrence (44) 
(AI). The safety of discontinuing secondary prophylaxis in HIV-infected children has not been studied 
extensively. 
Pregnant Women 
12. Chemoprophylaxis for PCP should be administered to pregnant women as is done for other adults and adolescents 
(AIII). TMP-SMZ is the recommended prophylactic agent; dapsone is an alternative. Because of theoretical concerns 
regarding possible teratogenicity associated with drug exposures during the first trimester, providers may choose to 
withhold prophylaxis during the first trimester. In such cases, aerosolized pentamidine may be considered because of its 
lack of systemic absorption and the resultant lack of exposure of the developing embryo to the drug (CIII). 
Toxoplasmic Encephalitis 
Prevention of Exposure 
1. HIV-infected persons should be tested for immunoglobulin G (IgG) antibody to Toxoplasma soon after the diagnosis 
of HIV infection to detect latent infection with Toxoplasma gondii (BIII). 
2. All HIV-infected persons, but particularly those who lack IgG antibody to Toxoplasma, should be counseled about the 
various sources of toxoplasmic infection. They should be advised not to eat raw or undercooked meat, particularly 
undercooked lamb, beef, pork, or venison (BIII). Specifically, lamb, beef, and pork should be cooked to an internal 
temperature of 165-170  F (44); meat cooked until it is no longer pink inside generally has an internal temperature of 
165-170 F and therefore from a more practical perspective, satisfies this requirement. HIV-infected persons should 
wash their hands after contact with raw meat and after gardening or other contact with soil; in addition, they should wash 
fruits and vegetables well before eating them raw (BIII). If the patient owns a cat, the litter box should be changed daily, 
preferably by an HIV-negative, nonpregnant person; alternatively, the patient should wash the hands thoroughly after 
changing the litter box (BIII). Patients should be encouraged to keep their cats inside and not to adopt or handle stray 
cats (BIII). Cats should be fed only canned or dried commercial food or well-cooked table food, not raw or undercooked 
meats (BIII). Patients need not be advised to part with their cats or to have their cats tested for toxoplasmosis (EII). 
Prevention of Disease 
Initiation of Primary Prophylaxis 
3. Toxoplasma-seropositive patients who have a CD4+ T-lymphocyte count of less than 100/µL should be administered 
prophylaxis against toxoplasmic encephalitis (TE) (AII) (25). The double-strength tablet daily dose of TMP-SMZ 
recommended as the preferred regimen for PCP prophylaxis appears to be effective against TE as well and is therefore 
recommended (AII) (25). If patients cannot tolerate TMP-SMZ, the recommended alternative is dapsone-pyrimethamine, 
which is also effective against PCP (BI) (29,30). Atovaquone with or without pyrimethamine also may be considered 
(CIII). Prophylactic monotherapy with dapsone, pyrimethamine, azithromycin, or clarithromycin cannot be 
recommended on the basis of current data (DII). Aerosolized pentamidine does not protect against TE and is not 
recommended (EI) (21,25). 
4. Toxoplasma-seronegative persons who are not taking a PCP prophylactic regimen known to be active against TE 
should be retested for IgG antibody to Toxoplasma when their CD4+ T-lymphocyte count declines below 100/µL to 
determine whether they have seroconverted and are therefore at risk for TE (CIII). Patients who have seroconverted 
should be administered prophylaxis for TE as described above (AII). 
Discontinuation of Primary Prophylaxis 
5. Prophylaxis against TE should be discontinued in adult and adolescent patients who have responded to 
HAART with an increase in CD4+ T-lymphocyte counts to > 200 cells/µL for at least 3 months (AI). 
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Several observational studies (37,41,47) and two randomized trials (38,46) have shown that primary prophylaxis 
can be discontinued with minimal risk of developing TE in patients who have responded to HAART with an 
increase in CD4+ T lymphocyte count from < 200 cells/µL to > 200 cells/µL for at least 3 months. In these studies, 
most patients were taking protease inhibitor-containing regimens and the median CD4+ T-lymphocyte count at 
the time prophylaxis was discontinued was >300 cells/µL. At the time prophylaxis was discontinued, many 
patients had sustained suppression of plasma HIV RNA levels below the detection limits of available assays; the 
median follow up ranged from 7 to 22 months 
While patients with CD4+ T lymphocyte counts of <100 cells/µL are at greatest risk for developing TE, the risk of 
TE occurring when the CD4+ T-lymphocyte count has increased to 100-200 cells/µL has not been studied as 
rigorously as a rise to >200 cells/µL. Thus, the recommendation specifies discontinuation of prophylaxis after an 
increase to >200 cells/µL. 
Discontinuation of primary TE prophylaxis is recommended not only because prophylaxis appears to add very 
little to disease prevention for toxoplasmosis, but also because discontinuation of drug reduces pill burden, the 
potential for drug toxicity, drug interaction, and selection of drug resistant pathogens. 
Restarting Primary Prophylaxis 
6. Prophylaxis should be reintroduced if the CD4+ T lymphocyte count decreases to <100-200 cells/µL (AIII). 
Prevention of Recurrence 
7. Patients who have completed initial therapy for TE should be administered lifelong suppressive therapy 
(secondary prophylaxis or chronic maintenance therapy) (AI) (48,49) unless immune reconstitution occurs as a 
consequence of HAART (see Recommendation #8 below). The combination of pyrimethamine plus sulfadiazine 
plus leucovorin is highly effective for this purpose (AI). A commonly used regimen for patients who cannot 
tolerate sulfa drugs is pyrimethamine plus clindamycin (BI); however, only the combination of pyrimethamine 
plus sulfadiazine appears to provide protection against PCP as well (AII). 
Discontinuation of Secondary Prophylaxis (Chronic Maintenance Therapy) 
8. Adult and adolescent patients receiving secondary prophylaxis (chronic maintenance therapy) for TE appear 
to be at low risk for recurrence of TE when they have successfully completed initial therapy for TE, remain 
asymptomatic with respect to signs and symptoms of TE, and have a sustained increase in their CD4+ T-
lymphocyte counts to >200 cells/µL following HAART (e.g., 6 months) (41,42,46). While the numbers of 
patients who have been evaluated remain small and occasional recurrences have been seen, based on these 
observations and on inference from more extensive cumulative data suggesting the safety of discontinuation of 
secondary prophylaxis for other OIs during advanced HIV disease, it is reasonable to consider discontinuation of 
chronic maintenance therapy in such patients (CIII). Some experts would obtain a magnetic resonance image of 
the brain as part of their evaluation to determine whether or not discontinuation of therapy is appropriate. 
Restarting Secondary Prophylaxis 
9. Secondary prophylaxis (chronic maintenance therapy) should be reintroduced if the CD4+ T lymphocyte count 
decreases to <200 cells/µL (AIII). 
Special Considerations 
Children 
10. TMP-SMZ, when administered for PCP prophylaxis, also provides prophylaxis against toxoplasmosis. Atovaquone 
might also provide protection (CIII). Children aged greater than 12 months who qualify for PCP prophylaxis and who are 
receiving an agent other than TMP-SMZ or atovaquone should have serologic testing for Toxoplasma antibody (BIII), 
because alternative drugs for PCP prophylaxis might not be effective against Toxoplasma. Severely immunosuppressed 
children who are not receiving TMP-SMZ or atovaquone who are found to be seropositive for Toxoplasma should be 
administered prophylaxis for both PCP and toxoplasmosis (i.e., dapsone plus pyrimethamine) (BIII).  Children with a 
history of toxoplasmosis should be administered lifelong prophylaxis to prevent recurrence (AI). The safety of 




11. TMP-SMZ can be administered for prophylaxis against TE as described for PCP (AIII). However, because of the low 
incidence of TE during pregnancy and the possible risk associated with pyrimethamine treatment, chemoprophylaxis 
with pyrimethamine-containing regimens can reasonably be deferred until after pregnancy (CIII). For prophylaxis 
against recurrent TE, the health-care provider and clinician should be well informed about the benefit of lifelong therapy 
and the concerns about teratogenicity of pyrimethamine.  Guidelines outlined in 7-9 above should be used when 
making decisions regarding secondary prophylaxis for TE in pregnancy. 
12. In rare cases, HIV-infected pregnant women who have serologic evidence of remote toxoplasmic infection have 
transmitted Toxoplasma to the fetus in utero. Pregnant HIV-infected women who have evidence of primary toxoplasmic 
infection or active toxoplasmosis (including TE) should be evaluated and managed during pregnancy in consultation 
with appropriate specialists (BIII). Infants born to women who have serologic evidence of infections with HIV and 
Toxoplasma should be evaluated for congenital toxoplasmosis (BIII). 
Cryptosporidiosis 
Prevention of Exposure 
1. HIV-infected persons should be educated and counseled about the many ways that Cryptosporidium can be 
transmitted (BIII). Modes of transmission include having direct contact with infected adults, diaper-aged children, and 
infected animals; drinking contaminated water; coming into contact with contaminated water during recreational 
activities; and eating contaminated food. 
2. HIV-infected persons should avoid contact with human and animal feces. They should be advised to wash their hands 
after contact with human feces (e.g., diaper changing), after handling pets, and after gardening or other contact with soil. 
HIV-infected persons should avoid sexual practices that might result in oral exposure to feces (e.g., oral-anal contact) 
(BIII). 
3. HIV-infected persons should be advised that newborn and very young pets might pose a small risk for transmitting 
cryptosporidial infection, but they should not be advised to destroy or give away healthy pets. Persons contemplating the 
acquisition of a new pet should avoid bringing any animal that has diarrhea into their households, should avoid 
purchasing a dog or cat aged less than 6 months, and should not adopt stray pets. HIV-infected persons who wish to 
assume the small risk for acquiring a puppy or kitten aged less than 6 months should request that their veterinarian 
examine the animal's stool for Cryptosporidium before they have contact with the animal (BIII). 
4. HIV-infected persons should avoid exposure to calves and lambs and to premises where these animals are raised (BII). 
5. HIV-infected persons should not drink water directly from lakes or rivers (AIII). 
6. Waterborne infection also might result from swallowing water during recreational activities. HIV-infected persons 
should be aware that many lakes, rivers, and salt-water beaches and some swimming pools, recreational water parks, and 
ornamental water fountains might be contaminated with human or animal waste that contains Cryptosporidium. They 
should avoid swimming in water that is likely to be contaminated and should avoid swallowing water while swimming 
or playing in recreational waters (BIII). 
7. Several outbreaks of cryptosporidiosis have been linked to municipal water supplies. During outbreaks or in other 
situations in which a community "boil-water" advisory is issued, boiling water for 1 minute will eliminate the risk for 
cryptosporidiosis (AI). Use of submicron personal-use water filters* (home/office types) and/or bottled water** also 
might reduce the risk (CIII). The magnitude of the risk for acquiring cryptosporidiosis from drinking water in a non-
outbreak setting is uncertain, and current data are inadequate to recommend that all HIV-infected persons boil water or 
avoid drinking tap water in non-outbreak settings. However, HIV-infected persons who wish to take independent action 
to reduce the risk for waterborne cryptosporidiosis may choose to take precautions similar to those recommended during 
outbreaks. Such decisions should be made in conjunction with health-care providers. Persons who opt for a personal-use 
filter or bottled water should be aware of the complexities involved in selecting appropriate products, the lack of 
enforceable standards for the destruction or removal of oocysts, the cost of the products, and the logistic difficulty of 
using these products consistently. 
8. Patients who take precautions to avoid acquiring cryptosporidiosis from drinking water should be advised that ice 
made from contaminated tap water also can be a source of infection (BII). Such persons also should be aware that 
fountain beverages served in restaurants, bars, theaters, and other places also might pose a risk because these beverages, 
as well as the ice they contain, are made from tap water. Nationally distributed brands of bottled or canned carbonated 
soft drinks are safe to drink. Commercially packaged non-carbonated soft drinks and fruit juices that do not require 
refrigeration until after they are opened (i.e., those that can be stored unrefrigerated on grocery shelves) also are safe. 
Nationally distributed brands of frozen fruit juice concentrate are safe if they are reconstituted by the user with water 
from a safe source. Fruit juices that must be kept refrigerated from the time they are processed to the time of 
consumption might be either fresh (unpasteurized) or heat-treated (pasteurized); only those juices labeled as pasteurized 
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should be considered free of risk from Cryptosporidium. Other pasteurized beverages and beers also are considered safe 
to drink (BII). No data are available concerning survival of Cryptosporidium oocysts in wine. 
9. HIV-infected persons should avoid eating raw oysters because cryptosporidial oocysts can survive in oysters for more 
than 2 months and have been found in oysters taken from some commercial oyster beds (BIII). Cryptosporidium-infected 
patients should not work as food handlers, especially if the food to be handled is intended to be eaten without cooking 
(BII). Because most food-borne outbreaks of cryptosporidiosis are believed to have been caused by infected food 
handlers, more specific recommendations to avoid exposure to contaminated food cannot be made. 
10. In a hospital, standard precautions (i.e., use of gloves and hand washing after removal of gloves) should be sufficient 
to prevent transmission of cryptosporidiosis from an infected patient to a susceptible HIV-infected person (BII). 
However, because of the potential for fomite transmission, some experts recommend that HIV-infected persons, 
especially those who are severely immunocompromised, should not share a room with a patient with cryptosporidiosis 
(CIII). 
Prevention of Disease 
11. Rifabutin or clarithromycin, when taken for Mycobacterium avium complex prophylaxis, have been found to 
protect against cryptosporidiosis (50, 51). However, data are insufficient at this time to warrant a 
recommendation for using these drugs as chemoprophylaxis for cryptosporidiosis. 
Prevention of Recurrence 
12. No drug regimens are known to be effective in preventing the recurrence of cryptosporidiosis. 
Special Considerations 
Children 
13. At present, no data indicate that formula-preparation practices for infants should be altered in an effort to prevent 
cryptosporidiosis (CIII). However, in the event of a "boil-water" advisory, similar precautions for the preparation of 
infant formula should be taken as for drinking water for adults (AII). 
Microsporidiosis 
Prevention of Exposure 
1. Other than general attention to hand washing and other personal hygiene measures, no precautions to reduce exposure 
can be recommended at this time. 
Prevention of Disease 
2. No chemoprophylactic regimens are known to be effective in preventing microsporidiosis. 
Prevention of Recurrence 
3. No chemotherapeutic regimens are known to be effective in preventing the recurrence of microsporidiosis. 
*Only filters capable of removing particles 1 µm in diameter should be considered. Filters that provide the greatest assurance of oocyst removal 
include those that operate by reverse osmosis, those labeled as absolute 1-µm filters, and those labeled as meeting NSF (National Sanitation 
Foundation) standard no. 53 for cyst removal. The nominal 1-µm filter rating is not standardized, and many filters in this category might not be capable 
of removing 99% of oocysts. For a list of filters certified as meeting NSF standards, consult the International Consumer Line at 800-673-8010 or 
http://www.nsf.org/notice/crypto.html. 
**Sources of bottled water (e.g., wells, springs, municipal tap-water supplies, rivers, and lakes) and methods for its disinfection differ; therefore, all 
brands should not be presumed to be free of cryptosporidial oocysts. Water from wells and springs is much less likely to be contaminated by oocysts 
than water from rivers or lakes. Treatment of bottled water by distillation or reverse osmosis ensures oocyst removal. Water passed through an absolute 
1-µm filter or a filter labeled as meeting NSF standard no. 53 for cyst removal before bottling will provide nearly the same level of protection. Use of 
nominal 1-µm filters by bottlers as the only barrier to Cryptosporidia might not result in the removal of 99% of oocysts. For more information, the 




Prevention of Exposure 
1. HIV-infected persons should be advised that certain activities and occupations might increase the likelihood of 
exposure to tuberculosis (BIII). These include volunteer work or employment in health-care facilities, correctional 
institutions, and shelters for the homeless, as well as in other settings identified as high risk by local health authorities. 
Decisions about whether to continue with activities in these settings should be made in conjunction with the health-care 
provider and should be based on factors such as the patient's specific duties in the workplace, the prevalence of 
tuberculosis in the community, and the degree to which precautions are taken to prevent the transmission of tuberculosis 
in the workplace (BIII). Whether the patient continues with such activities might affect the frequency with which 
screening for tuberculosis needs to be conducted. 
Prevention of Disease 
2. When HIV infection is first recognized, the patient should receive a tuberculin skin test (TST) by administration of 
intermediate-strength (5-TU) purified protein derivative (PPD) by the Mantoux method (AI). Routine evaluation for 
anergy is not recommended. However, there are selected situations in which anergy evaluation might assist in guiding 
individual decisions about preventive therapy (52,53). 
3. All HIV-infected persons who have a positive TST result (greater than or equal to 5 mm of induration) should undergo 
chest radiography and clinical evaluation to rule out active tuberculosis. HIV-infected persons who have symptoms 
suggestive of tuberculosis should promptly undergo chest radiography and clinical evaluation regardless of their TST 
status (AII). 
4. All HIV-infected persons, regardless of age, who have a positive TST result yet have no evidence of active 
tuberculosis and no history of treatment for active or latent tuberculosis should be treated for latent TB infection. 
Options include isoniazid daily (AII) or twice weekly (BII) for 9 months; 4 months of therapy daily with either 
rifampin (BIII) or rifabutin (CIII); or 2 months of therapy with either rifampin and pyrazinamide (BI) or 
rifabutin and pyrazinamide (CIII) (52-54). There have been reports of fatal and severe liver injury associated 
with the treatment of latent TB infection in HIV-uninfected persons treated with the 2 month regimen of daily 
rifampin and pyrazinamide; therefore it may be prudent to use regimens that do not contain pyrazinamide in 
HIV-infected persons whose completion of treatment can be assured. (CDC. Update: Fatal and Severe Liver 
Injuries Associated with Rifampin and Pyrazinamide for Latent Tuberculosis Infection and Revisions in 
American Thoracic Society/CDC Recommendations, United States 2001 MMWR 50 (No. 34), Aug 31, 2001). 
Because HIV-infected persons are at risk for peripheral neuropathy, those receiving isoniazid should also receive 
pyridoxine (BIII). A decision to use a regimen containing either rifampin or rifabutin should be made after careful 
consideration of potential drug interactions, especially those related to protease inhibitors and nonnucleoside reverse 
transcriptase inhibitors (see Special Considerations/Drug Interactions, page 15). Directly observed therapy should be 
used with intermittent dosing regimens (AI) and when otherwise operationally feasible (BIII) (53). 
5. HIV-infected persons who are close contacts of persons who have infectious tuberculosis should be treated for latent 
TB infection -- regardless of their TST results, age, or prior courses of treatment -- after the diagnosis of active 
tuberculosis has been excluded (AII) (52-54). In addition to household contacts, such persons might also include contacts 
in the same drug-treatment or health-care facility, coworkers, and other contacts if transmission of TB is demonstrated. 
6. For persons exposed to isoniazid- and/or rifampin-resistant TB, the decision to use chemoprophylactic 
antimycobacterial agents other than isoniazid alone, rifampin or rifabutin alone, rifampin plus pyrazinamide, or 
rifabutin plus pyrazinamide should be based on the relative risk for exposure to resistant organisms and should be made 
in consultation with public health authorities (AII). 
7. TST-negative, HIV-infected persons from risk groups or geographic areas with a high prevalence of Mycobacterium 
tuberculosis infection might be at increased risk for primary or reactivation tuberculosis. However, the efficacy of 
treatment in this group has not been demonstrated. Decisions concerning the use of chemoprophylaxis in these situations 
must be considered individually. 
8. Although the reliability of the TST might diminish as the CD4+ T-lymphocyte count declines, annual repeat testing 
should be considered for HIV-infected persons who are TST-negative on initial evaluation and who belong to 
populations in which there is a substantial risk for exposure to M. tuberculosis (BIII). Clinicians should consider 
repeating the TST for persons whose initial skin test was negative and whose immune function has improved in 
response to HAART (i.e., those whose CD4+ T-lymphocyte count has increased to greater than 200 cells/µL) 
(BIII) (52). In addition to confirming tuberculous infection, TST conversion in an HIV-infected person should alert 
health-care providers to the possibility of recent M. tuberculosis transmission and should prompt notification of public 
health officials for investigation to identify a possible source case. 
9. The administration of bacille Calmette-Guerin (BCG) vaccine to HIV-infected persons is contraindicated because of 
its potential to cause disseminated disease (EII). 
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Prevention of Recurrence 
10. Chronic suppressive therapy for a patient who has successfully completed a recommended regimen of treatment for 
tuberculosis is not necessary (DII). 
Special Considerations 
Drug Interactions 
11. Rifampin can induce metabolism of all the protease inhibitors and nonnucleoside reverse transcriptase 
inhibitors. This can result in more rapid drug clearance and possibly subtherapeutic drug concentrations of most 
of these antiretroviral agents. Rifampin should not be co-administered with the following protease inhibitors and 
nonnucleoside reverse transcriptase inhibitors: amprenavir, indinavir, lopinavir/ritonavir, nelfinavir, saquinavir, 
and delavirdine (53). However, it may be used with ritonavir, ritonavir plus saquinavir, efavirenz, and possibly 
with nevirapine. Rifabutin is an acceptable alternative to rifampin but should not be used with the protease 
inhibitor hard-gel saquinavir or delavirdine; caution is advised if the drug is coadministered with soft-gel 
saquinavir, because data are sparse. Rifabutin can be administered at one-half the usual daily dose, i.e., reduce 
from 300 mg to 150 mg per day, with indinavir, nelfinavir, or amprenavir or with one-fourth the usual dose, i.e., 
150 mg every other day or three times a week, with ritonavir, ritonavir plus saquinavir, or lopinavir/ritonavir. 
When rifabutin is administered with indinavir as the sole protease inhibitor, the dose of indinavir should be 
increased from 800 mg every eight hours to 1,000 mg every eight hours. Pharmacokinetic data suggest that 
rifabutin at an increased dose can be administered with efavirenz; doses of 450-600 mg per day have been 
suggested (54). However, little information is available about appropriate dosing if a protease inhibitor is used 
concurrently with efavirenz and rifabutin; with such a combination the rifabutin dose might need to be reduced. 
Rifabutin can be used without dose adjustment with nevirapine. 
Children 
12. Infants born to HIV-infected mothers should have a TST (5-TU PPD) at or before the age of 9-12 months and should 
be retested at least once a year (AIII). HIV-infected children living in households with TST-positive persons should be 
evaluated for tuberculosis (AIII); children exposed to a person who has active tuberculosis should be administered 
preventive therapy after active tuberculosis has been excluded, regardless of their TST results (AII). 
Pregnant Women 
13. Chemoprophylaxis for tuberculosis is recommended during pregnancy for HIV-infected patients who have either a 
positive TST or a history of exposure to active tuberculosis, after active tuberculosis has been excluded (AIII). A chest 
radiograph should be obtained before treatment and appropriate abdominal/pelvic lead apron shields should be used to 
minimize radiation exposure to the embryo/fetus. When an HIV-infected person has not been exposed to drug-resistant 
TB, isoniazid daily or twice weekly is the prophylactic regimen of choice. Because of concerns regarding possible 
teratogenicity associated with drug exposures during the first trimester, providers may choose to 
initiate prophylaxis after the first trimester. Preventive therapy with isoniazid should be accompanied by pyridoxine to 
reduce the risk for neurotoxicity. Experience with rifampin or rifabutin during pregnancy is more limited, but anecdotal 
experience with rifampin has not been associated with adverse pregnancy outcomes. Pyrazinamide should generally be 
avoided, particularly in the first trimester because of lack of information concerning fetal effects. 
Disseminated Infection with Mycobacterium avium Complex 
Prevention of Exposure 
1. Organisms of the M. avium complex (MAC) are common in environmental sources such as food and water. Current 
information does not support specific recommendations regarding avoidance of exposure. 
Prevention of Disease 
Initiation of Primary Prophylaxis 
2. Adults and adolescents who have HIV infection should receive chemoprophylaxis against disseminated MAC disease 
if they have a CD4+ T-lymphocyte count of less than 50 cells/µL (AI) (55). Clarithromycin (56,57) or azithromycin (58) 
are the preferred prophylactic agents (AI). The combination of clarithromycin and rifabutin is no more effective than 
clarithromycin alone for chemoprophylaxis and is associated with a higher rate of adverse effects than either drug alone; 
this combination should not be used (EI) (58). The combination of azithromycin with rifabutin is more effective than 
azithromycin alone; however, the additional cost, increased occurrence of adverse effects, potential for drug interactions, 
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and absence of a difference in survival when compared with azithromycin alone do not warrant a routine 
recommendation for this regimen (CI) (58). In addition to their preventive activity for MAC disease, clarithromycin and 
azithromycin each confer protection against respiratory bacterial infections (BII). If clarithromycin or azithromycin 
cannot be tolerated, rifabutin is an alternative prophylactic agent for MAC disease although rifabutin-associated drug 
interactions make this agent difficult to use (BI) (54). Tolerance, cost, and drug interactions are among the issues that 
should be considered in decisions regarding the choice of prophylactic agents for MAC disease. Particular attention to 
interactions with antiretroviral protease inhibitors and nonnucleoside reverse transcriptase inhibitors is warranted (see 
Special Considerations/Drug Interactions). Before prophylaxis is initiated, disseminated MAC disease should be ruled 
out by clinical assessment, which might include obtaining a blood culture for MAC if warranted. Because treatment with 
rifabutin could result in the development of resistance to rifampin in persons who have active tuberculosis, active 
tuberculosis should also be excluded before rifabutin is used for prophylaxis. 
3. Although the detection of MAC organisms in the respiratory or gastrointestinal tract might predict the development of 
disseminated MAC infection, no data are available on the efficacy of prophylaxis with clarithromycin, azithromycin, 
rifabutin, or other drugs in patients with MAC organisms at these sites and a negative blood culture. Therefore, routine 
screening of respiratory or gastrointestinal specimens for MAC cannot be recommended (DIII). 
Discontinuation of Primary Prophylaxis 
4. Primary MAC prophylaxis should be discontinued in adult and adolescent patients who have responded to 
HAART with an increase in CD4+ T lymphocyte count to >100 cells/µL for at least 3 months (AI). 
Two large randomized, placebo controlled trials and observational data have shown that such patients can 
discontinue primary prophylaxis with minimal risk of developing MAC (37,59-61). Discontinuation of primary 
prophylaxis in patients meeting the criteria above is recommended not only because prophylaxis appears to add 
very little to disease prevention for MAC or for bacterial infections, but also because discontinuation of drug 
reduces pill burden, the potential for drug toxicity, drug interactions, selection of drug resistant pathogens, and 
cost. 
Restarting Primary Prophylaxis 
5. Primary prophylaxis should be reintroduced if the CD4+ T lymphocyte count decreases to 
< 50-100 cells/µL (AIII). 
Prevention of Recurrence 
6. Adult and adolescent patients with disseminated MAC should receive lifelong therapy (i.e., secondary 
prophylaxis or maintenance therapy) (AII), unless immune reconstitution occurs as a consequence of HAART 
(see Recommendation #7 below). Unless good clinical or laboratory evidence of macrolide resistance exists, the 
use of a macrolide (clarithromycin or, alternatively, azithromycin) is recommended in combination with 
ethambutol (AII) with or without rifabutin (CI) (62,63). Treatment of MAC disease with clarithromycin in a dose 
of 1,000 mg twice a day is associated with a higher mortality rate than has been observed with clarithromycin 
administered at 500 mg twice a day; thus, the higher dose should not be used (EI) (64,65). Clofazimine has been 
associated with adverse clinical outcomes in the treatment of MAC disease and should not be used (DII) (66). 
Discontinuation of Secondary Prophylaxis (Chronic Maintenance Therapy) 
7. Patients appear to be at low risk for recurrence of MAC when they have completed a course of at least 12 
months of treatment for MAC, remain asymptomatic with respect to MAC signs and symptoms, and have a 
sustained increase , e.g., 6 months, in their CD4+ T-lymphocyte counts to >100cells/µL following HAART. 
While the numbers of patients who have been evaluated remain small, and recurrences could occur (41,42,67-69), 
based on these observations and on inference from more extensive data suggesting the safety of discontinuation of 
secondary prophylaxis for other OIs during advanced HIV disease, it may be reasonable to consider 
discontinuation of chronic maintenance therapy in such patients (CIII). Some experts would obtain a blood 
culture for MAC, even in asymptomatic patients, prior to discontinuation of therapy, to substantiate that disease 
is no longer active. 
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Restarting Secondary Prophylaxis 




9. Rifabutin should not be administered to patients receiving certain protease inhibitors and nonnucleoside 
reverse transcriptase inhibitors because the complex interactions have been incompletely studied, and the clinical 
implications of those interactions are unclear (16,54) (see Special Considerations: Drug interactions in the 
Tuberculosis section, above). Protease inhibitors may increase clarithromycin levels, but no recommendation to 
adjust the dose of either clarithromycin or protease inhibitors can be made on the basis of existing data. 
Efavirenz can induce metabolism of clarithromycin. This may result in reduced serum concentration of 
clarithromycin but increased concentration of 14-OH clarithromycin, an active metabolite of clarithromycin. 
Although the clinical significance of this interaction is not known, the efficacy of clarithromycin in MAC 
prophylaxis could be reduced because of this interaction. Azithromycin pharmacokinetics are not affected by the 
cytochrome P450 system; azithromycin can be used safely in the presence of protease inhibitors and/or 
nonnucleoside reverse transcriptase inhibitors without concerns of drug interactions. 
Children 
10. HIV-infected children aged less than 13 years who have advanced immunosuppression also can develop 
disseminated MAC infections, and prophylaxis should be offered to high-risk children according to the following CD4+ 
T-lymphocyte thresholds: children aged greater than or equal to 6 years, less than 50 cells/µL; children aged 2-6 years, 
less than 75 cells/µL; children aged 1-2 years, less than 500 cells/µL; and children aged less than 12 months, less than 
750 cells/µL (AII). For the same reasons that clarithromycin and azithromycin are the preferred prophylactic agents for 
adults, they should also be considered for children (AII); oral suspensions of both agents are commercially available in 
the United States. No liquid formulation of rifabutin suitable for pediatric use is commercially available in the United 
States. Children with a history of disseminated MAC should be administered lifelong prophylaxis to prevent 
recurrence (AII). The safety of discontinuing MAC prophylaxis in children whose CD4+ T-lymphocyte counts 
have increased in response to HAART has not been studied. 
Pregnant Women 
11. Chemoprophylaxis for MAC disease should be administered to pregnant women as is done for other adults and 
adolescents (AIII). However, because of general concerns about administering drugs during the first trimester of 
pregnancy, some providers may choose to withhold prophylaxis during the first trimester. Animal studies and anecdotal 
evidence of safety in humans suggest that of the available agents, azithromycin is the drug of choice (BIII) (70). 
Experience with rifabutin is limited. Clarithromycin has been demonstrated to be a teratogen in animals and should be 
used with caution during pregnancy (71). For secondary prophylaxis (chronic maintenance therapy), azithromycin plus 
ethambutol are the preferred drugs (BIII) (70). 
Bacterial Respiratory Infections 
Prevention of Exposure 
1. Because Streptococcus pneumoniae and Haemophilus influenzae are common in the community, no effective way 
exists to reduce exposure to these bacteria. 
Prevention of Disease 
2. Adults and adolescents who have a CD4+ T-lymphocyte count of greater than or equal to 
200 cells/ L should be administered a single dose of 23-valent polysaccharide pneumococcal vaccine if they have 
not received this vaccine during the previous five years (BII) (72-76). One randomized placebo-controlled trial of 
pneumococcal vaccine in Africa paradoxically found an increase in pneumonia among vaccinated subjects (77). 
However, several observational studies in the United States have not identified increased risk associated with 
vaccination and have identified benefit in this group (72-76). Most experts believe that the potential benefit of 
pneumococcal vaccination in the United States outweighs the risk. Immunization should also be considered for 
patients with CD4+ T lymphocyte counts < 200 cells/µL, although there is no clinical evidence for efficacy (CIII). 
Revaccination may be considered for patients who were initially immunized when their CD4+ T lymphocyte 
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count was <200 cells/µL and whose CD4+ count has increased to > 200 cells/µL in response to HAART (CIII). The 
recommendation to vaccinate is increasingly pertinent because of the increasing incidence of invasive infections 
with drug-resistant (including TMP-SMZ-, macrolide-, and beta-lactam-resistant) strains of S. pneumoniae. 
3. The duration of the protective effect of primary pneumococcal vaccination is unknown. Periodic revaccination may be 
considered; an interval of 5 years has been recommended for persons not infected with HIV and also might be 
appropriate for persons infected with HIV (CIII) (75). There is, however, no evidence for clinical benefit from 
revaccination. 
4. The incidence of H. influenzae type B infection in adults is low. Therefore, H. influenzae type B vaccine is not 
generally recommended for adult use (DIII). 
5. TMP-SMZ, when administered daily for PCP prophylaxis, reduces the frequency of bacterial respiratory infections. 
This should be considered in the selection of an agent for PCP prophylaxis (AII). However, indiscriminate use of this 
drug (when not indicated for PCP prophylaxis or other specific reasons) might promote the development of TMP-SMZ-
resistant organisms. Thus, TMP-SMZ should not be prescribed solely to prevent bacterial respiratory infection (DIII). 
Similarly, clarithromycin administered daily and azithromycin administered weekly for MAC prophylaxis might be 
effective in preventing bacterial respiratory infections; this should be considered in the selection of an agent for 
prophylaxis against MAC disease (BII). However, these drugs should not be prescribed solely for preventing bacterial 
respiratory infection (DIII). 
6. An absolute neutrophil count that is depressed because of HIV disease or drug therapy is associated with an increased 
risk for bacterial infections, including pneumonia. To reduce the risk for such bacterial infections, providers may 
consider taking steps to reverse neutropenia, either by stopping myelosuppressive drugs (CII) or by administering 
granulocyte-colony-stimulating factor (G-CSF) (CII). 
Prevention of Recurrence 
7. Some clinicians may administer antibiotic chemoprophylaxis to HIV-infected patients who have very frequent 
recurrences of serious bacterial respiratory infections (CIII). TMP-SMZ, administered for PCP prophylaxis, and 
clarithromycin or azithromycin, administered for MAC prophylaxis, are appropriate for drug-sensitive organisms. 
However, providers should be cautious about using antibiotics solely for preventing the recurrence of serious bacterial 
respiratory infections because of the potential development of drug-resistant microorganisms and drug toxicity. 
Special Considerations 
Children 
8. HIV infected children, less than five years old should be administered H. influenzae type b vaccine (AII) and 
pneumococcal conjugate vaccine (78-80) (BII) in accordance with the guidelines of the Advisory Committee on 
Immunization Practices (73,75,78) and the American Academy of Pediatrics (79). Children aged greater than 2 
years should also receive the 23-valent polysaccharide pneumococcal vaccine (BII). Revaccination with a second 
dose of the 23 valent polysaccharide pneumococcal vaccine should generally be offered after 3-5 years to children 
aged less than or equal to 10 years and after 5 years to children aged greater than 10 years (BIII). 
9. To prevent serious bacterial infections in HIV-infected children who have hypogammaglobulinemia (IgG less than 
400 mg/dL), clinicians should use intravenous immunoglobulin (IVIG) (AI). Respiratory syncytial virus (RSV) IVIG 
(750 mg/kg), not monoclonal RSV antibody, may be substituted for IVIG during the RSV season to provide broad anti-
infective protection, if RSV IVIG is available. 
10. To prevent recurrence of serious bacterial respiratory infections, antibiotic chemoprophylaxis may be considered 
(BI). However, providers should be cautious about using antibiotics solely for this purpose because of the potential 
development of drug-resistant microorganisms and drug toxicity. The administration of IVIG should also be considered 
for HIV-infected children who have recurrent serious bacterial infections (BI), although such treatment might not 
provide additional benefit to children who are being administered daily TMP-SMZ. However, IVIG may be considered 
for children who have recurrent serious bacterial infections despite receiving TMP-SMZ or other antimicrobials (CIII) 
(81). 
Pregnant Women 
11. Pneumococcal vaccination is recommended during pregnancy for HIV-infected patients who have not been 
vaccinated during the previous 5 years (BIII). Among nonpregnant adults, vaccination has been associated with a 
transient burst of HIV replication. Whether the transient viremia can increase the risk for perinatal HIV transmission is 
unknown. Because of this concern, when feasible, vaccination may be deferred until after HAART has been initiated to 






Bacterial Enteric Infections 
Prevention of Exposure 
Food 
1. Health-care providers should advise HIV-infected persons not to eat raw or undercooked eggs (including foods that 
might contain raw eggs [e.g., some preparations of hollandaise sauce, Caesar and certain other salad dressings, some 
mayonnaises, uncooked cookie and cake batter, egg nog]); raw or undercooked poultry, meat, seafood (especially 
raw shellfish); unpasteurized dairy products; unpasteurized fruit juices; and raw seed sprouts (e.g., alfalfa sprouts, 
mung bean sprouts). Poultry and meat are safest when adequate cooking is confirmed with a thermometer 
(internal temperature of 180  F for poultry and 165 F for red meats). If a thermometer is not used, the risk of 
illness is decreased by consuming poultry and meat that have no trace of pink color. Color change of the meat 
(e.g., absence of pink) does not always correlate with internal temperature. (BIII). Produce should be washed 
thoroughly before being eaten (BIII). 
2. Health-care providers should advise HIV-infected persons to avoid cross-contamination of foods. Uncooked meats, 
(including hot dogs) and their juices should not come into contact with other foods. Hands, cutting boards, counters, 
knives, and other utensils should be washed thoroughly after contact with uncooked foods (BIII). 
3. Health-care providers should advise HIV-infected persons that, although the incidence of listeriosis is low, it is
 
a serious disease that occurs with unusually high frequency among severely immunosuppressed HIV-infected
 
persons. An immunosuppressed, HIV-infected person who wishes to reduce the risk of acquiring listeriosis as
 
much as possible may choose to do the following (CIII):
 
a) avoid soft cheeses (e.g., feta, Brie, Camembert, blue-veined and Mexican-style cheese such as queso fresco).
 




b) cook leftover foods or ready-to-eat foods (e.g., hot dogs) until steaming hot before eating;
 




d) avoid refrigerated pates and other meat spreads, or heat/reheat these foods until steaming. Canned or shelf-

stable pate and meat spreads need not be avoided;
 
e) avoid raw or unpasteurized milk (including goat’s milk) or milk-products, or foods which contain
 
unpasteurized milk or milk-products. (CIII).
 
Pets 
4. When obtaining a new pet, HIV-infected persons should avoid animals aged less than 6 months, especially those that 
have diarrhea (BIII). 
5. HIV-infected persons should avoid contact with animals that have diarrhea (BIII). HIV-infected pet owners should 
seek veterinary care for animals with diarrheal illness, and a fecal sample from such animals should be examined for 
Cryptosporidium, Salmonella, and Campylobacter. 
6. HIV-infected persons should wash their hands after handling pets (especially before eating) and should avoid contact 
with pets' feces (BIII). 
7. HIV-infected persons should avoid contact with reptiles (e.g., snakes, lizards, iguanas, and turtles) as well as chicks 
and ducklings because of the risk for salmonellosis (BIII). 
Travel 
8. The risk for food-borne and waterborne infections among immunosuppressed, HIV-infected persons is magnified 
during travel to developing countries. Persons who travel to such countries should avoid foods and beverages that might 
be contaminated, particularly raw fruits and vegetables, raw or undercooked seafood or meat, tap water, ice made with 
tap water, unpasteurized milk and dairy products, and items sold by street vendors (AII). Foods and beverages that are 
generally safe include steaming-hot foods, fruits that are peeled by the traveler, bottled (especially carbonated) 
beverages, hot coffee and tea, beer, wine, and water brought to a rolling boil for 1 minute (AII). Treatment of water with 
iodine or chlorine might not be as effective as boiling but can be used when boiling is not practical (BIII). 
Prevention of Disease 
9. Prophylactic antimicrobial agents are not generally recommended for travelers (DIII). The effectiveness of these 
agents depends on local antimicrobial-resistance patterns of gastrointestinal pathogens, which are seldom known. 
Moreover, these agents can elicit adverse reactions and can promote the emergence of resistant organisms. However, for 
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HIV-infected travelers, antimicrobial prophylaxis may be considered, depending on the level of immunosuppression and 
the region and duration of travel (CIII). The use of fluoroquinolones such as ciprofloxacin (500 mg per day) can be 
considered when prophylaxis is deemed necessary (CIII). As an alternative (e.g., for children, pregnant women, and 
persons already taking TMP-SMZ for PCP prophylaxis), TMP-SMZ might offer some protection against traveler's 
diarrhea (BIII). The risk of toxicity should be considered before treatment with TMP-SMZ is initiated solely because of 
travel. 
10. Antimicrobial agents such as fluoroquinolones should be given to patients before their departure, to be taken 
empirically (e.g., 500 mg of ciprofloxacin twice a day for 3-7 days) should significant traveler's diarrhea develop (BIII). 
Fluoroquinolones should be avoided for children aged less than 18 years and pregnant women, and alternative antibiotics 
should be considered (BIII). Travelers should consult a physician if their diarrhea is severe and does not respond to 
empirical therapy, if their stools contain blood, if fever is accompanied by shaking chills, or if dehydration develops. 
Antiperistaltic agents (e.g., loperamide) can be used to treat mild diarrhea. However, the use of these drugs should be 
discontinued if symptoms persist beyond 48 hours. Moreover, these agents should not be administered to patients who 
have a high fever or who have blood in the stool (AII). 
11. Some experts recommend that HIV-infected persons who have Salmonella gastroenteritis be administered 
antimicrobial therapy to prevent extraintestinal spread of the pathogen. However, no controlled study has demonstrated a 
beneficial effect of such treatment, and some studies of immunocompetent persons have suggested that antimicrobial 
therapy can lengthen the shedding period. The fluoroquinolones -- primarily ciprofloxacin (750 mg twice a day for 14 
days) -- can be used when antimicrobial therapy is chosen (CIII). 
Prevention of Recurrence 
12. HIV-infected persons who have Salmonella septicemia require long-term therapy (i.e., secondary prophylaxis or 
chronic maintenance therapy) to prevent recurrence. Fluoroquinolones, primarily ciprofloxacin, are usually the drugs of 
choice for susceptible organisms (BII). 
13. Household contacts of HIV-infected persons who have salmonellosis or shigellosis should be evaluated for persistent 
asymptomatic carriage of Salmonella or Shigella so that strict hygienic measures and/or antimicrobial therapy can be 
instituted and recurrent transmission to the HIV-infected person can be prevented (CIII). 
Special Considerations 
Children 
14. Like HIV-infected adults, HIV-infected children should wash their hands after handling pets (especially before 
eating) and should avoid contact with pets' feces. Hand washing should be supervised (BIII). 
15. HIV-exposed infants aged less than 3 months and all HIV-infected children who have severe immunosuppression 
should be administered treatment for Salmonella gastroenteritis to prevent extraintestinal spread of the pathogen (CIII). 
Choices of antibiotics include TMP-SMZ, ampicillin, cefotaxime, ceftriaxone, or chloramphenicol; fluoroquinolones 
should be used with caution and only if no alternatives exist. 
16. HIV-infected children who have Salmonella septicemia should be offered long-term therapy to prevent recurrence 
(CIII). TMP-SMZ is the drug of choice; ampicillin or chloramphenicol can be used if the organism is susceptible. 
Fluoroquinolones should be used with caution and only if no alternative exists. 
17. Antiperistaltic drugs are not recommended for children (DIII). 
Pregnant Women 
18. Because both pregnancy and HIV infection confer a risk for listeriosis, pregnant HIV-infected women should heed 
recommendations regarding listeriosis (BII). 
19. Because extraintestinal spread of Salmonella during pregnancy might lead to infection of the placenta and amniotic 
fluid and result in pregnancy loss similar to that seen with Listeria monocytogenes, pregnant women with Salmonella 
gastroenteritis should receive treatment (BIII). Choices for treatment include ampicillin, cefotaxime, ceftriaxone, or 
TMP-SMZ. Fluoroquinolones should be avoided. 
20. Fluoroquinolones should not be used during pregnancy. TMP-SMZ might offer some protection against traveler's 
diarrhea. 
Bartonellosis 
Prevention of Exposure 
1. HIV-infected persons, particularly those who are severely immunosuppressed, are at unusually high risk for 
developing relatively severe disease due to infection with Bartonella, which can be transmitted from cats. These persons 
should consider the potential risks of cat ownership (CIII). Persons who acquire a cat should adopt or purchase an animal 
aged greater than 1 year that is in good health (BII). 
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2. Although declawing is not generally advised, HIV-infected persons should avoid rough play with cats and situations in 
which scratches are likely (BII). Any cat-associated wound should be washed promptly (CIII). Cats should not be 
allowed to lick open wounds or cuts of HIV-infected persons (BIII). 
3. Care of cats should include flea control (CIII). 
4. No evidence indicates any benefits to cats or their owners from routine culture or serologic testing of the pet for 
Bartonella infection (DII). 
Prevention of Disease 
5. No data support chemoprophylaxis for Bartonella-associated disease (CIII). 
Prevention of Recurrence 
6. Relapse or reinfection with Bartonella has sometimes followed a course of primary treatment. Although no firm 
recommendation can be made regarding prophylaxis in this situation, long-term suppression of infection with 
erythromycin or doxycycline should be considered (CIII). 
Special Considerations 
Children 
7. The risks of cat ownership for HIV-infected children who are severely immunocompromised should be discussed with 
parents and caretakers (CIII). 
Pregnant Women 
8. If long-term suppression of Bartonella infection is required, erythromycin should be used. Tetracycline should not be 
used during pregnancy. 
Candidiasis 
Prevention of Exposure 
1. Candida organisms are common on mucosal surfaces and skin. No measures are available to reduce exposure to these 
fungi. 
Prevention of Disease 
2. Data from prospective controlled trials indicate that fluconazole can reduce the risk for mucosal (oropharyngeal, 
esophageal, and vaginal) candidiasis and cryptococcosis as well in patients with advanced HIV disease (75-77). 
However, routine primary prophylaxis is not recommended because of the effectiveness of therapy for acute disease, the 
low mortality associated with mucosal candidiasis, the potential for resistant Candida organisms to develop, the 
possibility of drug interactions, and the cost of prophylaxis (DIII). 
Prevention of Recurrence 
3. Many experts do not recommend chronic prophylaxis of recurrent oropharyngeal or vulvovaginal candidiasis for the 
same reasons that they do not recommend primary prophylaxis. However, if recurrences are frequent or severe, providers 
may consider administering an oral azole (fluconazole [CI] [82-84] or itraconazole solution [CI]). Other factors that 
influence choices about such therapy include the impact of the recurrences on the patient's well-being and quality of life, 
the need for prophylaxis for other fungal infections, cost, toxicities, drug interactions, and the potential to induce drug 
resistance among Candida and other fungi. Prolonged use of systemically absorbed azoles, particularly in patients with 
low CD4+ T-lymphocyte counts (i.e., less than 100 cells/µL), increases the risk for the development of azole resistance. 
4. Adults or adolescents who have a history of documented esophageal candidiasis, particularly multiple episodes, should 
be considered candidates for chronic suppressive therapy. Fluconazole at a dose of 100-200 mg daily is appropriate (BI). 







5. Primary prophylaxis of candidiasis in HIV-infected infants is not indicated (DIII). 
6. Suppressive therapy with systemic azoles should be considered for infants who have severe recurrent mucocutaneous 
candidiasis (CIII) and particularly for those who have esophageal candidiasis (BIII). 
Pregnant Women 
7. Experience is limited with the use of systemic antifungal drugs during human pregnancy. Four cases of infants born 
with craniofacial and skeletal abnormalities following prolonged in utero exposure to fluconazole have been reported 
(85,86). In addition, itraconazole is embryotoxic and teratogenic in animal systems (87). These same potential risks of 
teratogenicity are presumed to apply to other systemically absorbed azole antifungals, such as ketoconazole. Therefore, 
chemoprophylaxis against oropharyngeal, esophageal, or vaginal candidiasis using systemically absorbed azoles should 
not be initiated during pregnancy (DIII), and azoles should be discontinued for HIV-infected women who become 
pregnant (DIII). Effective birth control measures should be recommended to all HIV-infected women on azole therapy 
for candidiasis (AIII). 
Cryptococcosis 
Prevention of Exposure 
1. HIV-infected persons cannot completely avoid exposure to Cryptococcus neoformans. No evidence exists that 
exposure to pigeon droppings is associated with an increased risk for acquiring cryptococcosis. 
Prevention of Disease 
2. Routine testing of asymptomatic persons for serum cryptococcal antigen is not recommended because of the low 
probability that the results will affect clinical decisions (DIII). 
3. Prospective controlled trials indicate that fluconazole and itraconazole can reduce the frequency of cryptococcal 
disease among patients who have advanced HIV disease. However, most experts recommend that antifungal prophylaxis 
not be used routinely to prevent cryptococcosis because of the relative infrequency of cryptococcal disease, the lack of 
survival benefits associated with prophylaxis, the possibility of drug interactions, the potential development of antifungal 
drug resistance, and cost. The need for prophylaxis or suppressive therapy for other fungal infections (e.g., candidiasis, 
histoplasmosis, or coccidioidomycosis) should be considered in making decisions about prophylaxis for cryptococcosis. 
If used, fluconazole at doses of 100-200 mg daily is reasonable for patients whose CD4+ T-lymphocyte counts are less 
than 50 cells/µL (CI) (82). 
Prevention of Recurrence 
4. Patients who have completed initial therapy for cryptococcosis should be administered lifelong suppressive treatment, 
(i.e., secondary prophylaxis or chronic maintenance therapy) (AI) unless immune reconstitution occurs as a 
consequence of HAART (see Recommendation #5 below). Fluconazole is superior to itraconazole in preventing 
relapse of cryptococcal disease and is the preferred drug (AI) (88-90). 
Discontinuation of Secondary Prophylaxis (Chronic Maintenance Therapy) 
5. Adult and adolescent patients appear to be at low risk for recurrence of cryptococcosis when they have 
successfully completed a course of initial therapy for cryptococcosis, remain asymptomatic with respect to signs 
and symptoms of cryptococcosis, and have a sustained increase (e.g., 6 months) in their CD4+ T-lymphocyte 
counts to >100-200 cells/µL following HAART. The numbers of patients who have been evaluated remain small 
(91,92). Based on these observations and on inference from more extensive data suggesting the safety of 
discontinuation of secondary prophylaxis for other OIs during advanced HIV disease, and while recurrences 
could occur it may be reasonable to consider discontinuation of chronic maintenance therapy in such patients 
(CIII). Some experts would perform a lumbar puncture to determine if the CSF is culture negative before 
stopping therapy even if patients have been asymptomatic; other experts do not believe this is necessary. 
Restarting Secondary Prophylaxis 







7. No data exist on which to base specific recommendations for children, but lifelong suppressive therapy with 
fluconazole after an episode of cryptococcosis is appropriate (AIII). 
Pregnant Women 
8. Prophylaxis with fluconazole or itraconazole should not be initiated during pregnancy because of the low incidence of 
cryptococcal disease, the lack of a recommendation for primary prophylaxis against cryptococcosis in nonpregnant 
adults, and potential teratogenic effects of these drugs during pregnancy (DIII) (85,86). For patients who conceive while 
being administered primary prophylaxis and who elect to continue their pregnancy, prophylaxis should be discontinued. 
The occurrence of craniofacial and skeletal abnormalities in infants following prolonged in utero exposure to fluconazole 
should be considered when assessing the therapeutic options for HIV-infected women who become pregnant and are 
receiving secondary prophylaxis (chronic maintenance therapy) for cryptococcosis (85,86). If a woman meets the 
criteria for discontinuation of secondary prophylaxis as discussed above, strong consideration should be given to 
discontinuing therapy during pregnancy as long as the CD4+ T lymphocyte could remains above 100-200 cells/µL. 
For patients requiring therapy, amphotericin B may be preferred, especially during the first trimester. Effective birth 
control measures should be recommended to all HIV-infected women on azole therapy for cryptococcosis (AIII). 
Histoplasmosis 
Prevention of Exposure 
1. Although HIV-infected persons living in or visiting histoplasmosis-endemic areas cannot completely avoid exposure 
to Histoplasma capsulatum, those whose CD4+ T-lymphocyte counts are less than 200 cells/µL should avoid activities 
known to be associated with increased risk (e.g., creating dust when working with surface soil; cleaning chicken coops 
that are heavily contaminated with droppings; disturbing soil beneath bird-roosting sites; cleaning, remodeling, or 
demolishing old buildings; and exploring caves) (CIII). 
Prevention of Disease 
2. Routine skin testing with histoplasmin and serologic testing for antibody or antigen in histoplasmosis-endemic areas 
are not predictive of disease and should not be performed (DII). 
3. Data from a prospective randomized controlled trial indicate that itraconazole can reduce the frequency of 
histoplasmosis among patients who have advanced HIV infection and who live in H. capsulatum-endemic areas (93). 
However, no survival benefit was observed among persons receiving itraconazole. Prophylaxis with itraconazole may be 
considered in patients with CD4+ T-lymphocyte counts less than 100 cells/µL who are at especially high risk because of 
occupational exposure or who live in a community with a hyperendemic rate of histoplasmosis (greater than or equal to 
10 cases per 100 patient-years) (CI). 
Prevention of Recurrence 
4. Patients who complete initial therapy for histoplasmosis should be administered lifelong suppressive treatment (i.e., 
secondary prophylaxis or chronic maintenance therapy) with itraconazole (200 mg twice a day) (AI) (94). 
Discontinuation of Secondary Prophylaxis (Chronic Maintenance Therapy) 
5. Although patients receiving secondary prophylaxis (chronic maintenance therapy) might be at low risk for recurrence 
of systemic mycosis when their CD4+ T-lymphocyte counts increase to greater than 100 cells/µL, in response to 




6. Because primary histoplasmosis can lead to disseminated infection in children, a reasonable option is to administer 
lifelong suppressive therapy after an acute episode of the disease (AIII). 
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Pregnant Women 
7. Because of the embryotoxicity and teratogenicity of itraconazole in animal systems, primary prophylaxis against 
histoplasmosis should not be offered during pregnancy (DIII) (80). These data as well as the observation of craniofacial 
and skeletal abnormalities in infants following prolonged in utero exposure to fluconazole (85,86) should be considered 
when assessing the need for chronic maintenance therapy in HIV-infected pregnant women with histoplasmosis. For 
such patients, therapy with amphotericin B may be preferred, especially during the first trimester. For women receiving 
HAART with a sustained rise in CD4+ T lymphocyte counts above 100 cells/µL, discontinuation of azole 
prophylaxis, especially during the first trimester, should be considered. Effective birth control measures should be 
recommended to all HIV-infected women on azole therapy for histoplasmosis (AIII). 
Coccidioidomycosis 
Prevention of Exposure 
1. Although HIV-infected persons living in or visiting areas in which coccidioidomycosis is endemic cannot completely 
avoid exposure to Coccidioides immitis, they should, when possible, avoid activities associated with increased risk (e.g., 
those involving extensive exposure to disturbed native soil, for example, at building excavation sites or during dust 
storms) (CIII). 
Prevention of Disease 
2. Routine skin testing with coccidioidin (spherulin) in coccidioidomycosis-endemic areas is not predictive of disease 
and should not be performed (DII). Within the endemic area, a positive serologic test might indicate an increased risk for 
active infection; however, routine testing does not appear to be useful and should not be performed (DIII). 
3. Primary prophylaxis for HIV-infected persons who live in coccidioidomycosis-endemic areas is not routinely 
recommended. 
Prevention of Recurrence 
4. Patients who complete initial therapy for coccidioidomycosis should be administered lifelong suppressive therapy (i.e., 
secondary prophylaxis or chronic maintenance therapy) (AII) using either 400 mg of fluconazole by mouth each day or 
200 mg of itraconazole twice a day (95). Patients with meningeal disease require consultation with an expert. 
Discontinuation of Secondary Prophylaxis (Chronic Maintenance Therapy) 
5. Although patients receiving secondary prophylaxis (chronic maintenance therapy) might be at low risk for recurrence 
of systemic mycosis when their CD4+ T-lymphocyte counts increase to greater than 100 cells/µL, in response to 




6. Although no specific data are available regarding coccidioidomycosis in HIV-infected children, a reasonable option is 
to administer lifelong suppressive therapy after an acute episode of the disease (AIII). 
Pregnant Women 
7. The potential teratogenicity of fluconazole (85,86) and itraconazole (80) should be considered when assessing the 
therapeutic options for HIV-infected women who become pregnant while receiving chronic maintenance therapy for 
coccidioidomycosis. For such patients, therapy with amphotericin B may be preferred, especially during the first 
trimester. For women receiving HAART with a sustained rise in CD4+ T lymphocyte counts above 100 cells/µL, 
discontinuation of azole prophylaxis, especially during the first trimester, should be considered. Effective birth 
control measures should be recommended for all HIV-infected women on azole therapy for coccidioidomycosis (AIII). 
Cytomegalovirus Disease 
Prevention of Exposure 
1. HIV-infected persons who belong to risk groups with relatively low rates of seropositivity for cytomegalovirus (CMV) 
and who therefore cannot be presumed to be seropositive should be tested for antibody to CMV (BIII). These groups 
include patients who have not had male homosexual contact or used injection drugs. 
2. HIV-infected adolescents and adults should be advised that CMV is shed in semen, cervical secretions, and saliva and 
that latex condoms must always be used during sexual contact to reduce the risk for exposure to CMV and to other 
sexually transmitted pathogens (AII). 
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3. HIV-infected adults and adolescents who are child-care providers or parents of children in child-care facilities should 
be informed that they are at increased risk for acquiring CMV infection (BI). Similarly, parents and other caretakers of 
HIV-infected children should be advised of the increased risk to children at these centers (BIII). The risk for acquiring 
CMV infection can be diminished by good hygienic practices such as hand washing (AII). 
4. HIV-exposed infants and HIV-infected children, adolescents, and adults who are seronegative for CMV and require 
blood transfusion should be administered only CMV antibody-negative or leukocyte-reduced cellular blood products in 
nonemergency situations (BIII). 
Prevention of Disease 
5. Prophylaxis with oral ganciclovir may be considered for HIV-infected adults and adolescents who are CMV 
seropositive and who have a CD4+ T-lymphocyte count of less than 50 cells/µL (CI) (96,97). Ganciclovir-induced 
neutropenia, anemia, conflicting reports of efficacy, lack of proven survival benefit, the risk for developing ganciclovir-
resistant CMV, and cost are among the issues that should be considered when deciding whether to institute prophylaxis 
in individual patients. Acyclovir is not effective in preventing CMV disease, and valacyclovir is not recommended 
because of an unexplained trend toward increased deaths among persons with AIDS who were administered valacyclovir 
for CMV prophylaxis (98). Therefore, neither acyclovir nor valacyclovir should be used for this purpose (EI). The most 
important method for preventing severe CMV disease is recognition of the early manifestations of the disease. Early 
recognition of CMV retinitis is most likely when the patient has been educated on this topic. Patients should be made 
aware of the significance of increased floaters in the eye and should be advised to assess their visual acuity regularly by 
using simple techniques such as reading newsprint (BIII). Regular funduscopic examinations performed by an 
ophthalmologist are recommended by some experts for patients with low (e.g., less than 50 cells/µL) CD4+ T-
lymphocyte counts (CIII). 
Prevention of Recurrence 
6. CMV disease is not cured with courses of the currently available antiviral agents (e.g., ganciclovir, foscarnet, 
cidofovir, or fomivirsen). Following induction therapy, secondary prophylaxis (chronic maintenance therapy) is 
recommended for life (AI), unless there is immune reconstitution as a consequence of HAART (see 
recommendation #7 below). Regimens demonstrated to be effective for chronic suppression in randomized, controlled 
clinical trials include parenteral or oral ganciclovir, parenteral foscarnet, combined parenteral ganciclovir and foscarnet, 
parenteral cidofovir, and (for retinitis only) ganciclovir administration via intraocular implant or repetitive 
intravitreous injections of fomivirsen (AI) (99-107). Oral valganciclovir has been approved by the FDA for both 
acute induction therapy and for maintenance therapy although much of the data have not been published. 
Repetitive intravitreous injections of ganciclovir, foscarnet, and cidofovir have been reported to be effective for 
secondary prophylaxis of CMV retinitis in uncontrolled case series (108,109) Intraocular therapy alone does not 
provide protection to the contralateral eye or to other organ systems and typically is combined with oral ganciclovir (99). 
The choice of a chronic maintenance regimen for patients treated for CMV disease should be made in consultation with 
an expert. For patients with retinitis, this decision should be made in consultation with an ophthalmologist and should 
take into consideration the anatomic location of the retinal lesion, vision in the contralateral eye, the immunologic and 
virologic status of the patient, and the patient's response to HAART (BIII). 
Discontinuation of Secondary Prophylaxis (Chronic Maintenance Therapy) 
7. Several case series have reported that maintenance therapy can be discontinued safely in adult and adolescent 
patients with CMV retinitis whose CD4+ T-lymphocyte counts have shown a sustained (e.g., 6 months) increase 
to > 100-150 cells/µL in response to HAART (110-115). These patients have remained disease-free for greater 
than 30-95 weeks, whereas in the pre-HAART era, retinitis typically reactivated within 6-8 weeks after stopping 
CMV therapy. Plasma HIV RNA levels were variable in these patients, suggesting that the CD4+ T-lymphocyte 
count is the primary determinant of immune recovery to CMV. Discontinuation of prophylaxis should be 
considered in patients with a sustained, (e.g., 6 months) increase in CD4+ T-lymphocyte count to >100-150 
cells/ L in response to HAART (BII). Such decisions should be made in consultation with an ophthalmologist and 
should take into account such factors as magnitude and duration of CD4+ T-lymphocyte increase, anatomic 
location of the retinal lesion, vision in the contralateral eye, and the feasibility of regular ophthalmologic 
monitoring (BII). All patients who have had anti-CMV maintenance therapy discontinued should continue to 
undergo regular ophthalmologic monitoring for early detection of CMV relapse (as well as for immune 
reconstitution uveitis) (AIII). CMV viral load or other markers of CMV infection, e.g., antigenemia, or viral DNA 
tests are not well standardized; their role in predicting relapse remains to be defined (116-117). Relapses have 
been reported rarely in patients with CD4+ T lymphocyte count >100-150 cells/µL (118). 
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Restarting Secondary Prophylaxis 
8. Relapse of CMV retinitis occurs in patients whose anti-CMV maintenance therapy has been discontinued and 
whose CD4+ T-lymphocyte count has decreased to 50 cells/ L (108). Therefore, reinstitution of secondary 
prophylaxis should be reinstituted when the CD4+ T-lymphocyte count has decreased to 100-150 cells/ L (AIII). 
Relapse has been reported in patients whose CD4+ T lymphocyte counts are higher then 100 cells/µL, but such 
reports are rare to date (118). 
Special Considerations 
Children 
9. Some experts recommend obtaining a CMV urine culture on all HIV-infected (or exposed) infants at birth or at an 
early postnatal visit to identify those infants with congenital CMV infection (CIII). In addition, beginning at 1 year of 
age, CMV antibody testing on an annual basis may be considered for CMV-seronegative (and culture-negative) HIV-
infected infants and children who are severely immunosuppressed (Table 9) (CIII). Annual testing will allow 
identification of children who have acquired CMV infection and might benefit from screening for retinitis. 
10. HIV-infected children who are CMV-infected and severely immunosuppressed might benefit from a dilated retinal 
examination performed by an ophthalmologist every 4-6 months (CIII). In addition, older children should be counseled 
to be aware of floaters in the eye, similar to the recommendation for adults (BIII). 
11. Oral ganciclovir results in reduced CMV shedding in CMV-infected children and may be considered for primary 
prophylaxis against CMV disease in CMV-infected children who are severely immunosuppressed (e.g., CD4+ T-
lymphocyte count less than 50 cells/µL) (CII). 
12. Patients with a history of CMV disease should be administered lifelong prophlyaxis to prevent recurrence 
(AII).  For children with CMV disease, no data are available to guide decisions concerning discontinuation of secondary 
prophylaxis (chronic maintenance therapy) when the CD4+ T-lymphocyte count has increased in response to HAART. 
Pregnant Women 
13. Indications for prophylaxis are the same for pregnant women as for non-pregnant women. The choice of 
agents to be used in pregnancy should be individualized after consultation with experts. 
Herpes Simplex Virus Disease 
Prevention of Exposure 
1. HIV-infected persons should use latex condoms during every act of sexual intercourse to reduce the risk for exposure 
to herpes simplex virus (HSV) and to other sexually transmitted pathogens (AII). They should specifically avoid sexual 
contact when herpetic lesions (genital or orolabial) are evident (AII). 
Prevention of Disease 
2. Antiviral prophylaxis after exposure to HSV, or to prevent initial episodes of HSV disease in individuals with latent 
infection is not recommended (DIII). 
Prevention of Recurrence 
3. Because episodes of HSV disease can be treated successfully, chronic therapy with acyclovir is not required after 
lesions resolve. However, persons who have frequent or severe recurrences can be administered daily suppressive 
therapy with oral acyclovir or oral famciclovir (AI) (119-120). Valacyclovir also is an option (CIII). Intravenous 
foscarnet or cidofovir can be used to treat infection due to acyclovir-resistant isolates of HSV, which are routinely 
resistant to ganciclovir as well (AII). 
Special Considerations 
Children 
4. The recommendations for preventing initial disease and recurrence among adults and adolescents apply to children as 
well. 
Pregnant Women 
5. Oral acyclovir prophylaxis during late pregnancy is a controversial strategy recommended by some experts to prevent 
neonatal herpes transmission. However, such prophylaxis is not routinely recommended. For patients who have frequent, 
severe recurrences of genital HSV disease, acyclovir prophylaxis might be indicated (BIII). No pattern of adverse 
pregnancy outcomes has been reported after acyclovir exposures (121). 
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Varicella-Zoster Virus Disease 
Prevention of Exposure 
1. HIV-infected children and adults who are susceptible to varicella-zoster virus (VZV) (i.e., those who have no history 
of chickenpox or shingles or are seronegative for VZV) should avoid exposure to persons with chickenpox or shingles 
(AII). Household contacts (especially children) of susceptible HIV-infected persons should be vaccinated against VZV if 
they have no history of chickenpox and are seronegative for HIV, so that they will not transmit VZV to their susceptible 
HIV-infected contacts (BIII). 
Prevention of Disease 
2. Very little data regarding the safety and efficacy of varicella vaccine in HIV-infected adults are available, and no 
recommendation for its use can be made for this population. (See Special Considerations/Children, below, for 
information about the use of varicella vaccine in children.) 
3. For the prophylaxis of chickenpox, HIV-infected children and adults who are susceptible to VZV (i.e., those who have 
no history of chickenpox or shingles or who have no detectable antibody against VZV) should be administered varicella 
zoster immune globulin (VZIG) as soon as possible but within 96 hours after close contact with a patient who has 
chickenpox or shingles (AIII). Data are lacking on the effectiveness of acyclovir for preventing chickenpox in 
susceptible HIV-infected children or adults. 
4. No preventive measures are currently available for shingles. 
Prevention of Recurrence 
5. No drug has been proven to prevent the recurrence of shingles in HIV-infected persons. 
Special Considerations 
Children 
6. HIV-infected children who are asymptomatic and not immunosuppressed (i.e., in immunologic category 1, Table 9) 
should receive live attenuated varicella vaccine at 12-15 months of age or later (BII). Varicella vaccine should not be 
administered to other HIV-infected children because of the potential for disseminated viral infection (EIII). 
Pregnant Women 
7. VZIG is recommended for VZV-susceptible, HIV-infected pregnant women within 96 hours after exposure to VZV 
(AIII). If oral acyclovir is used, VZV serology should be performed so that the drug can be discontinued if the patient is 
seropositive for VZV (BIII). 
Human Herpesvirus 8 Infection (Kaposi’s Sarcoma-Associated Herpes Virus) 
Prevention of Exposure 
1. Persons co-infected with HIV and HHV-8 are at risk for developing Kaposi’s sarcoma (KS), and, there is 
evidence that progression to KS may be accelerated in individuals who seroconvert to HHV-8 after being infected 
with HIV. Thus it is important to prevent acquisition of HHV-8 infections in those already infected with HIV 
(122-124). The three major routes of HHV-8 transmission appear to be oral (the virus infects oral epithelial cells, 
and infection has been associated with deep kissing in one study), via semen (HHV-8 is less frequently detected in 
semen than in saliva), and through blood via needle sharing (125-127). Patients should be counseled that deep 
kissing and sexual intercourse with individuals who have high risk of being infected with HHV-8, e.g., persons 
who have KS or who are infected with HIV, may lead to acquisition of the agent that causes KS (CIII). Although 
the efficacy of condom use for preventing HHV-8 exposure has not been established, HIV-infected persons should 




(AII). HIV-infected injection drug users should be counseled to not share drug injection equipment, even if both 
users are already HIV-infected, because of the chance of becoming infected with HHV-8 or other bloodborne 
pathogens (BIII). 
Prevention of Disease 
2. Because clinical use of routine serologic testing to identify HHV-8 infection has not been established, no 
recommendation for serologic testing can be made at this time. 
3. Lower rates of KS have been observed among AIDS patients treated with ganciclovir or foscarnet for CMV retinitis 
(98). HHV-8 replication in vitro is inhibited by ganciclovir, foscarnet, and cidofovir. However, because the efficacy and 
clinical use of these drugs in preventing KS have not been established, no recommendation can be made concerning the 
use of these or other drugs to prevent KS in individuals coinfected with HIV and HHV-8. 
4. Potent antiretroviral drug combinations that suppress HIV replication reduce the frequency of KS in HIV-infected 
persons (128) and should be considered for all persons who qualify for such therapy (BII). 
Prevention of Recurrence 
5. Effective suppression of HIV replication with antiretroviral drugs in HIV-infected patients with KS might prevent KS 
progression or the development of new lesions and should be considered for all persons with KS (BII). 
Special Considerations 
Children 
6. In parts of the world where HHV-8 is endemic, mother-to-child transmission of HHV-8 has been reported and (129-
132) horizontal transmission among young children, possibly via saliva occurs. However, no recommendations are 
currently available for preventing HHV-8 transmission from child to child. 
Human Papillomavirus Infection 
Prevention of Exposure 
1. HIV-infected persons should use latex condoms during every act of sexual intercourse to reduce the risk for exposure 
to sexually transmitted pathogens (AII), although little evidence exists to suggest that condoms reduce the risk for 
infection with human papillomavirus (HPV). 
Prevention of Disease 
HPV-associated Genital Epithelial Cancers in HIV-infected Women 
2. After a complete history of previous cervical disease has been obtained, HIV-infected women should have a pelvic 
examination and a Pap smear. In accordance with the recommendation of the Agency for Health Care Policy and 
Research, the Pap smear should be obtained twice in the first year after diagnosis of HIV infection and, if the results are 
normal, annually thereafter (AII). 
3. If the results of the Pap smear are abnormal, care should be provided according to the Interim Guidelines for 
Management of Abnormal Cervical Cytology published by a National Cancer Institute Consensus Panel and briefly 
summarized in Recommendations 4-8, which follow (133). 
4. For patients whose Pap smears are interpreted as atypical squamous cells of undetermined significance (ASCUS), 
several management options are available; the choice depends in part on whether the interpretation of ASCUS is 
qualified by a statement indicating that a neoplastic process is suspected. Follow-up by Pap tests without colposcopy is 
acceptable, particularly when the diagnosis of ASCUS is not qualified further or the cytopathologist suspects a reactive 
process. In such situations, Pap tests should be repeated every 4-6 months for 2 years until three consecutive smears have 
been negative. If a second report of ASCUS occurs in the 2-year follow-up period, the patient should be considered for 
colposcopic evaluation (BIII). 
5. Women who have a diagnosis of unqualified ASCUS associated with severe inflammation should be evaluated for an 
infectious process. If specific infections are identified, reevaluation should be performed after appropriate treatment, 
preferably after 2-3 months (BIII). 
6. If the diagnosis of ASCUS is qualified by a statement indicating that a neoplastic process is suspected, the patient 
should be managed as if a low-grade squamous intraepithelial lesion (LSIL) were present (see Recommendation 7, which 
follows) (BIII). If a patient who has a diagnosis of ASCUS is at high risk (i.e., previous positive Pap tests or poor 
adherence to follow-up), the option of colposcopy should be considered (BIII). 
7. Several management options are available for patients who have LSIL. Follow up with Pap tests every 4-6 months is 












management. Patients managed in this way must be carefully selected and considered reliable for follow-up. If repeat 
smears show persistent abnormalities, colposcopy and directed biopsy are indicated (BIII). Colposcopy and directed 
biopsy of any abnormal area on the ectocervix constitute another appropriate option (BIII). 
8. Women who have cytologic diagnosis of high-grade squamous intraepithelial lesions (HSILs) or squamous cell 
carcinoma should undergo colposcopy and directed biopsy (AII). 
9. No data are available to suggest that these guidelines to prevent cervical disease should be modified for women on 
HAART. 
HPV-associated Anal Intraepithelial Neoplasia and Anal Cancer in HIV-infected Men Who Have Sex With Men 
and in Women 
10. Evidence from several studies shows that HPV-positive men who have sex with men and HPV infected women are at 
increased risk for anal HSILs and might be at increased risk for anal cancer. In view of this evidence, coupled with a 
recent cost-effectiveness analysis projecting that screening and treatment for anal HSILs provide clinical benefits 
comparable to other measures to prevent OIs in HIV-infected persons (130), anal cytology screening of HIV-infected 
men who have sex with men and women might become a useful preventive measure in the near future. However, further 
studies of screening and treatment programs for anal HSILs need to be carried out before recommendations for routine 
anal cytology screening can be made. 
Prevention of Recurrence 
11. The risks for recurrence of squamous intraepithelial lesions and cervical cancer after conventional therapy are 
increased among HIV-infected women. The prevention of illness associated with recurrence depends on careful follow-
up of patients after treatment. Patients should be monitored with frequent cytologic screening and, when indicated, with 
colposcopic examination for recurrent lesions (AI) (133,143). 
12. In one recent study of HIV-infected women treated for HSILs using standard therapy, low-dose intravaginal 5-
fluorouracil (2 grams twice a week for 6 months) reduced the short-term risk for recurrence and possibly the grade of 




13. Use of intravaginal 5-fluorouracil to prevent recurrent dysplasia is not recommended during pregnancy. 
Hepatitis C Virus Infection 
Prevention of Exposure 
1. The chief route of hepatitis C virus (HCV) transmission in the United States is injection drug use. Because injection 
drug use is a complex behavior, clinicians should assess the individual's readiness to change this practice and encourage 
efforts to provide patient education and support directed at recovery. 
Patients who inject drugs should be advised (136-138) --
•	 to stop using injection drugs (AIII); 
•	 to enter and complete a substance-abuse treatment program, including a relapse prevention program (AIII). 
If they are continuing to inject drugs (BIII) -
•	 to never reuse or share syringes, needles, rinse water, or drug preparation equipment; if, nonetheless, injection 
equipment that has been used by other persons is shared, to first clean the equipment with bleach and water as is 
recommended for prevention of HIV; 
•	 to use only sterile syringes obtained from a reliable source (e.g., pharmacies or syringe exchange programs); 
•	 to use sterile (e.g., boiled) water to prepare drugs; if not possible, to use clean water from a reliable source (e.g., 
fresh tap water); 
•	 to use a new or disinfected container ("cooker") and a new filter ("cotton") to prepare drugs; 
•	 to clean the injection site with a new alcohol swab before injection; and 
•	 to safely dispose of syringes after one use. 
2. Persons considering tattooing or body piercing should be informed of potential risks of acquiring bloodborne 
infections, which could be transmitted if equipment is not sterile or if proper infection control procedures are not 
followed (e.g., washing hands, using latex gloves, and cleaning and disinfecting surfaces) (138) (BIII). 
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3. To reduce risks for acquiring bloodborne infections, patients should be advised not to share dental appliances, razors, 
or other personal care articles (BIII). 
4. Although the efficiency of sexual transmission of HCV is low, safe-sexual practices should be encouraged for all HIV 
infected persons, and barrier precautions (e.g., latex condoms) are recommended to reduce the risk for exposure to 
sexually transmitted pathogens (AII). 
Prevention of Disease 
5. All patients with HIV infection should be screened for HCV infection (BIII). Screening is recommended because 
some HIV-infected patients (e.g., injection drug users, and patients with hemophilia) are at increased risk for 
HCV infection and HCV related disease, and because knowledge of HCV status is important for management of 
all HIV-infected patients (e.g., to interpret and manage elevated liver related tests). Screening should be 
performed by using enzyme immunoassays (EIAs) licensed for detection of antibody to HCV (anti-HCV) in blood 
(BIII). Positive anti-HCV results should be verified with additional testing (i.e., recombinant immunoblot assay 
[RIBA™] or reverse transcriptase polymerase chain reaction for HCV RNA). The presence of HCV RNA in blood might 
also be assessed in HIV-infected persons with undetectable antibody but other evidence of chronic liver disease (e.g., 
unexplained elevated liver-specific enzymes) or when acute HCV infection is suspected (CIII). 
6. Persons coinfected with HIV and HCV should be advised not to drink excessive amounts of alcohol (AII). Avoiding 
alcohol altogether might be prudent because it is unclear whether even occasional alcohol use (e.g., less than 12 ounces 
of beer or less than 10 grams of alcohol per day) increases the incidence of cirrhosis among HCV-infected persons 
(CIII). 
7. Patients with chronic hepatitis C should be vaccinated against hepatitis A because a) the risk for fulminant hepatitis 
associated with hepatitis A appears increased in such patients; b) hepatitis A vaccine is safe for HIV-infected persons; 
and c) although immunogenicity is reduced in patients with advanced HIV infection, more than two thirds of patients 
develop protective antibody responses (BIII). Prevaccination screening for total (IgG and IgM) antibody to hepatitis A 
virus is cost-effective and therefore recommended when greater than 30% prevalence of hepatitis A virus antibody is 
expected in the population being screened (e.g., persons greater than 40 years of age) (139). Patients should also be 
immunized for HBV if they are susceptible (BIII). 
8. HIV-HCV-coinfected patients may develop HCV associated liver disease over a shorter time course than patients 
infected with HCV alone (140-143) and should be evaluated for chronic liver disease and for the possible need for 
treatment. Limited data suggest that HCV treatment can be safely provided to patients coinfected with HIV and 
HCV. Because the optimal means of treating coinfected patients has not been established and many HIV-infected 
patients have conditions that complicate therapy (e.g., depression), this care should occur in a clinical trial or be 
coordinated by providers with experience treating both HIV and HCV infections (BIII). 
9. In some studies, the incidence of antiretroviral-associated liver enzyme elevations has been increased in patients 
coinfected with HIV and HCV (141); such increases might not require treatment modifications. Thus, although liver 
enzymes should be carefully monitored, HAART should not be routinely withheld from patients coinfected with HIV 
and HCV (DIII). However, coinfected patients initiating HAART might have an inflammatory reaction that mimics an 
exacerbation of underlying liver disease. In this situation, careful monitoring of liver function is required. 
Prevention of Recurrence 
10. If the serum HCV RNA level becomes undetectable during HCV therapy and remains undetectable for 6 months 
after HCV therapy is stopped (sustained virologic response), greater than 90% of HIV-uninfected patients with hepatitis 
C will remain HCV RNA negative for greater than 5 years and have improved liver histology (144). For HIV-HCV-
coinfected patients, the durability of treatment response and requirement for maintenance therapy are unknown. 
Special Considerations 
Children 
11. Transmission of HCV from mother to child appears to be more frequent for mothers co-infected with HIV 
and HCV than for those infected with HCV alone. Therefore, children born to women coinfected with HIV and 
HCV should be tested for HCV infection (136) (BI). Because maternal HCV antibody can persist for up to 18 months, 
testing should be performed at or after 2 years of age. If earlier diagnosis is desired, RT-PCR for HCV RNA may be 
performed after 1 month of age and should be repeated at a subsequent time. The average rate of HCV infection among 
infants born to coinfected women is approximately 15% (range, 5-36%) (145). Data are limited on the natural history of 
HCV infection and treatment of chronic hepatitis C in children. 
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TABLE 1. Prophylaxis to Prevent First Episode of Opportunistic Disease in Adults and 
Adolescents Infected with Human Immunodeficiency Virus 
Preventive Regimens 
Pathogen Indication First Choice Alternatives 
I. Strongly recommended as standard of care 
Pneumocystis carinii1 CD4+ count <200/µL Trimethoprim- Dapsone, 50 mg po 
or oropharyngeal sulfamethoxazole b.i.d. or 100 mg po 
candidiasis (TMP-SMZ), 1 DS po q.d. (BI); dapsone, 50 
q.d. (AI) mg po q.d. plus 
pyrimethamine, 
TMP-SMZ, 1 SS po 50 mg po q.w. plus 
q.d. (AI) leucovorin 25 mg po 
q.w. (BI); dapsone 
200 mg po plus 
pyrimethamine, 
75 mg po plus 
leucovorin, 25 mg po 
q.w. (BI); aerosolized 




atovaquone, 1500 mg 
po q.d. (BI); TMP-




 Isoniazid-sensitive2 TST reaction ≥5 mm Isoniazid, 300 mg po Rifampin, 600 mg 
or prior positive TST 
result without 
plus pyridoxine, 
50 mg po q.d. x 9 mo 
po q.d. (BIII) x 4 mo 
or rifabuin 300 mg 
treatment or contact (AII) or isoniazid, po q.d. (CIII) x 4 
with case of active 900 mg po plus mo 
tuberculosis pyridoxine, 100 mg po 
regardless of TST b.i.w. x 9 mo (BII) Pyrazinamide, 15-20 
result (BIII) mg/kg po q.d. x 2 
mo plus either 
rifampin, 600 mg po 
q.d. (BI) x 2 mo or 
rifabutin, 300 mg po 
q.d. (CIII) x 2 mo
 Isoniazid-resistant Same as above; high Rifampin 600 mg po Pyrazinamide 
probability of (AIII) or rifabutin, 15-20 mg/kg po q.d. 
exposure to isoniazid- 300 mg po (BIII) q.d. plus either rifampin, 
resistant tuberculosis x 4 mo 600 mg po (BI) or 
rifabutin, 300 mg po 
(CIII) q.d. x 2 mo
 Multidrug-(isoniazid and rifampin) resistant Same as above; high Choice of drugs ------
probability of requires consultation 
exposure to multidrug- with public health 
resistant tuberculosis authorities. Depends 
on susceptibility of 
isolate from source 
patient 
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TABLE 1. Prophylaxis to Prevent First Episode of Opportunistic Disease in Adults and 
Adolescents Infected with Human Immunodeficiency Virus (continued) 
Preventive Regimens 
Pathogen Indication First Choice Alternatives 
Toxoplasma gondii3 IgG antibody to TMP-SMZ, 1 DS po TMP-SMZ, 1 SS po 
Toxoplasma and q.d. (AII) q.d. (BIII): dapsone, 
CD4+ count <100/µL 50 mg po q.d. plus 
pyrimethamine, 
50 mg po q.w. plus 
leucovorin, 25 mg po 
q.w. (BI); dapsone, 200 
mg po plus 
pyrimethamineˆ, 75 mg 
po plus leucovorin, 25 mg 
po q w (BI); atovaquone, 
1500 mg po q.d. with 
or without 
pyrimethamine, 
25 mg po q.d. plus 




CD4+ count <50/µL Azithromycin, 
1,200 mg po q.w., (AI) 
or clarithromycin,4 
Rifabutin, 300 mg po 
q.d. (BI); 
azithromycin, 
500 mg po b.i.d. (AI) 1,200 mg po q.w. plus 
rifabutin, 300 mg po 
q.d. (CI) 
Varicella zoster virus Significant exposure Varicella zoster 
(VZV) to chickenpox or immune globulin 
shingles for patients (VZIG), 5 vials 
who have no history 
of either condition or, 
(1.25 mL each) im, 
administered ≤96 h 
if available, negative after exposure, ideally 
antibody to VZV within 48 h (AIII) 
II. Generally Recommended 
Streptococcus 
pneumoniae5 
CD4+ count > 200/µL 23 valent poly-
saccharide 
None 
vaccine, 0.5 mL im [BII] 
Hepatitis B virus6,7 All susceptible Hepatitis B vaccine: None 
(anti-HBc-negative) 3 doses (BII) 
patients 
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TABLE 1. Prophylaxis to Prevent First Episode of Opportunistic Disease in Adults and 
Adolescents Infected with Human Immunodeficiency Virus - continued 
Preventive Regimens 
Pathogen	 Indication First Choice Alternatives 
Influenza virus6,8	 All patients (annually, Inactivated Oseltamivir, 75 mg 
before influenza trivalent influenza virus po q.d. (influenza A  or B) 
season) vaccine: one annual dose (CIII); rimantadine, 100 mg 
(0.5 mL) im (BIII) po b.i.d. (CIII), or 
amantadine, 100 mg 
po b.i.d. (CIII) 
(influenza A only) 
Hepatitis A virus6,7 All susceptible Hepatitis A vaccine: None 
(anti-HAV-negative) two doses (BIII) 
patients at increased 
risk for HAV infection 
(e.g., illicit drug users, 
men who have sex with 
men, hemophiliacs) or 
with chronic liver disease, 
including chronic hepatitis 
B or hepatitis C 
III. Evidence for Efficacy but Not Routinely Indicated
 Bacteria Neutropenia 	 Granulocyte- None 
colony-stimulating 
factor (G-CSF), 
5-10 µg/kg sc q.d. x 




250 µg/m2 sc iv 
x 2-4 w (CII) 
Cryptococcus CD4+ count <50/µL Fluconazole, Itraconazole capsule, 
neoformans 100-200 mg po q.d. 200 mg po q.d. (CIII) 
(CI) 
Histoplasma CD4+ count <100/µL, Itraconazole capsule, None 
Capsulatum9 endemic geographic 200 mg po q.d.(CI) 
area
 Cytomegalovirus CD4+ count <50/µL Oral ganciclovir, 1g None
 (CMV)10 and CMV antibody po t.i.d. (CI) 
positivity 
NOTES: Information included in these guidelines might not represent Food and Drug Administration (FDA) approval or approved labeling for the 
particular products or indications in question. Specifically, the terms "safe" and "effective" might not be synonymous with the FDA-defined legal 
standards for product approval. The Respirgard IITM nebulizer is manufactured by Marquest, Englewood, Colorado. Letters and Roman numerals in 
parentheses after regimens indicate the strength of the recommendation and the quality of evidence supporting it (see page 7). 
ABBREVIATIONS: Anti-HBc = antibody to hepatitis B core antigen; b.i.w.= twice a week; DS = double-strength tablet; HAART = highly active 
antiretroviral therapy; HAV = hepatitis A virus; HIV = human immunodeficiency virus; im = intramuscular; iv = intravenous; po = by mouth; q.d. = 
daily; q.m. = monthly; q.w. = weekly; SS= single-strength tablet; t.i.w. = three times a week; TMP-SMZ = trimethoprim-sulfamethoxazole; sc = 
subcutaneous; and TST = tuberculin skin test. 
1Prophylaxis should also be considered for persons with a CD4+ percentage of <14%, for persons with a history of an AIDS-defining illness, and 
possibly for those with CD4+ counts >200 but <250 cells/µL. TMP-SMZ also reduces the frequency of toxoplasmosis and some bacterial infections. 





100 mg q.d. The efficacy of parenteral pentamidine (e.g., 4 mg/kg/month) is uncertain. Fansidar (sulfadoxine-pyrimethamine) is rarely used because of 
severe hypersensitivity reactions. Patients who are being administered therapy for toxoplasmosis with 
sulfadiazine-pyrimethamine are protected against Pneumocystis carinii pneumonia and do not need additional prophylaxis against PCP. 
2Directly observed therapy is recommended for isoniazid, e.g., 900 mg b.i.w.; isoniazid regimens should include pyridoxine to prevent peripheral 
neuropathy. If rifampin or rifabutin are administered concurrently with protease inhibitors or non-nucleoside reverse transcriptase inhibitors, 
careful consideration should be given to potential pharmacokinetic interactions (54). See discussion of rifamycin interactions in paragraph 11 
in section on Tuberculosis. There have been reports of fatal and severe liver injury associated with the treatment of latent TB infection in 
HIV-uninfected persons treated with the 2 month regimen of daily rifampin and pyrazinamide; therefore it may be prudent to use regimens 
that do not contain pyrazinamide in HIV-infected persons whose completion of treatment can be assured (CDC. Update: Fatal and Severe 
Liver Injuries Associated with Rifampin and Pyrazinamide for Latent Tuberculosis Infection and Revisions in American Thoracic 
Society/CDC Recommendations, United States 2001 MMWR 50 (No. 34), Aug 31, 2001). Exposure to multidrug-resistant tuberculosis might 
require prophylaxis with two drugs; consult public health authorities. Possible regimens include pyrazinamide plus either ethambutol or a 
fluoroquinolone. 
3Protection against toxoplasmosis is provided by TMP-SMZ, dapsone plus pyrimethamine, and possibly by atovaquone. Atovaquone may be used with 
or without pyrimethamine. Pyrimethamine alone probably provides little, if any, protection. 
4See paragraph 9, in section on “Disseminated Infection with Mycobacterium avium complex” and references 53-54 for discussion of drug 
interactions. 
*During pregnancy, azithromycin is preferred over clarithromycin because of the teratogenicity in animals of clarithromycin. 
5Vaccination may be offered to persons who have a CD4+ T-lymphocyte count <200 cells/µL, although the efficacy is likely to be diminished. 
Revaccination 5 years after the first dose or sooner if the initial immunization was given when the CD4+ count was <200 cells/µL and the CD4+ count 
has increased to >200 cells/µL on HAART is considered optional. Some authorities are concerned that immunizations might stimulate the replication 
of HIV. 
6Although data demonstrating  clinical benefit of these vaccines in HIV-infected persons are not available, it is logical to assume that those 
patients who develop antibody responses will derive some protection. Some authorities are concerned that immunizations might stimulate HIV 
replication, although for influenza vaccination, a large observational study of HIV-infected persons in clinical care showed no adverse effect of this 
vaccine, including multiple doses, on patient survival (J. Ward, CDC, personal communication). Also, this concern may be less relevant in the 
setting of HAART. However, because of the theoretical concern that increases in HIV plasma RNA following vaccination during pregnancy 
might increase the risk of perinatal transmission of HIV, providers may wish to defer vaccination for such patients until after HAART is 
initiated. 
7Hepatitis B vaccine has been recommended for all children and adolescents and for all adults with risk factors for hepatitis B virus (HBV). 
For persons requiring vaccination against both hepatitis A and hepatitis B, a combination vaccine is now available. For additional 
information regarding vaccination against hepatitis A and B, see CDC. Hepatitis B virus: a comprehensive strategy for eliminating 
transmission in the United States through universal childhood vaccination. Recommendations of the Advisory Committee on Immunization 
Practices (ACIP). MMWR 1991;40 (No RR13). 
8Oseltamivir is appropriate during outbreaks of either influenza A or influenza B. Rimantadine or amantadine are appropriate during 
outbreaks of influenza A (although neither rimantadine nor amantadine is recommended during pregnancy). Dosage reduction for antiviral 
chemoprophylaxis against influenza might be indicated for decreased renal or hepatic function, and for persons with seizure disorders. 
Physicians should consult the drug package inserts and the annual CDC influenza guidelines for more specific information about adverse 
effects and dosage adjustments. For additional information about vaccination, antiviral chemoprophylaxis and therapy against influenza, see: 
CDC. Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 
2001;50(No. RR-4). 
9In a few unusual occupational or other circumstances, prophylaxis should be considered; consult a specialist.
 
10Acyclovir is not protective against CMV. Valacyclovir is not recommended because of an unexplained trend toward increased mortality observed in
 




                                                    
                        
 
          
 
 
TABLE 2. Prophylaxis to Prevent Recurrence of Opportunistic Disease in Adults (after chemotherapy for acute 
disease) in Adults and Adolescents Infected with Human Immunodeficiency Virus 
Preventive Regimens 
Pathogen	 Indication First Choice Alternatives 
Recommended as standard of care 
Pneumocystis carinii	 Prior P. carinii 
pneumonia 
Toxoplasma gondii1	 Prior toxoplasmic 
encephalitis 
Mycobacterium Documented 
avium complex2 disseminated 
disease 




(TMP-SMZ), 1 DS po 
q.d. (AI); 
TMP-SMZ 1 SS po 
q.d. (AI) 
Sulfadiazine, 500-1,000 
mg po q.i.d. plus 
pyrimethamine, 
25-50 mg po q.d. plus 
leucovorin, 10-25 mg 
po q.d. (AI) 
Clarithromycin,2 500 mg 
po b.i.d. (AI) plus 
ethambutol, 15 mg/kg po 
q.d. (AII); with or without 
rifabutin, 300 mg po q.d. (CI) 
Ganciclovir, 5-6 mg/kg/day iv 
5-7 days/wk or 1,000 mg 
po t.i.d. (AI); or foscarnet, 
90-120 mg/kg iv q.d. (AI); 
or (for retinitis) ganciclovir 
sustained-release implant 
q 6-9 months plus 
ganciclovir, 1.0-1.5 g po 
t.i.d. (AI); 
Dapsone, 50 mg po 
b.i.d. or 100 mg po 
q.d. (BI); dapsone, 
50 mg po q.d. plus 
pyrimethamine, 
50 mg po q.w. plus 
leucovorin, 25 mg po 
q.w. (BI); dapsone, 
200 mg po plus 
pyrimethamine, 75 mg 
po plus leucovorin, 25 
mg po q.w. (BI); 
aerosolized 
pentamidine, 
300 mg q.m. via 
Respirgard IITM 
nebulizer (BI); 
atovaquone, 1500 mg 
po q.d. (BI); TMP-
SMZ, 1 DS po t.i.w. 
(CI) 
Clindamycin, 300-450 
mg po q 6-8 h plus 
pyrimethamine, 25-50 
mg po q.d. plus, 
leucovorin 10-25 mg 
po q.d. (BI); 
atovaquone 750 mg po 
q 6-12 h with 
or without 
pyrimethamine, 25 mg 
po q.d. plus 
leucovorin, 10 
mg po, q.d. (CIII) 
Azithromycin, 500 mg 
po q.d. (AII) plus 
ethambutol, 15 mg/kg 
po q.d.(AII); with 
or without rifabutin, 
300 mg po q.d. (CI) 
Cidofovir, 5 mg/kg iv 
q.o.w. with probenecid 
2 grams po 3 hours 
before the dose 
followed by 1 gram po 
2 hours after the dose, 
and 1 gram po 8 hours 
after the dose (total of 
4 grams) (AI). 
Fomivirsen 1 vial (330 
µg) injected into the 
vitreous, then repeated 
every 2-4 wks (AI); 
valganciclovir 900 mg po 
q.d. (BI) 
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TABLE 2. Prophylaxis to Prevent Recurrence of Opportunistic Disease in Adults (after chemo-therapy for acute 
disease) in Adults and Adolescents Infected with Human Immunodeficiency Virus (continued) 
Preventive Regimens 
Pathogen	 Indication First Choice Alternatives 
Cryptococcus Documented Fluconazole, 200 mg po	 Amphotericin B, 
neoformans disease q.d. (AI)	 0.6-1.0 mg/kg iv 
q.w.-t.i.w. (AI); 
itraconazole, 200 mg 
capsule po q.d. (BI) 
Histoplasma Documented Itraconazole capsule, Amphotericin B, 
capsulatum disease 200 mg po b.i.d. (AI) 1.0 mg/kg iv q.w. (AI) 
Coccidioides Documented Fluconazole, 400 mg po	 Amphotericin B, 
immitis disease q.d. (AII)	 1.0 mg/kg iv q.w. (AI); 
itraconazole, 200 mg 
capsule po b.i.d. (AII) 
Salmonella species, Bacteremia Ciprofloxacin, 500 mg po Antibiotic 
(non-typhi)3 b.i.d. for several months chemoprophylaxis 
(BII) with another active 
agent (CIII) 
II. Recommended only if subsequent episodes are frequent or severe 
Herpes simplex virus	 Frequent/severe Acyclovir, 200 mg po t.i.d Valacyclovir, 500 mg 
recurrences or 400 mg po b.i.d.(AI) po b.i.d. (CIII) 
Famciclovir 250 mg po 
b.i.d. (AI) 
Candida Frequent/severe Fluconazole 100-200 mg Itraconazole solution, 
(oropharyngeal or recurrences po q.d. (CI) 200 mg po q.d. (CI); 
vaginal) 
Candida (esophageal)	 Frequent/severe Fluconazole 100-200 mg Itraconazole solution, 
recurrences po q.d. (BI) 200 mg po q.d. (BI); 
NOTES: Information included in these guidelines might not represent Food and Drug Administration (FDA) approval or approved labeling for
 
the particular products or indications in question. Specifically, the terms "safe" and "effective" might not be synonymous with the FDA-defined
 
legal standards for product approval. The Respirgard II(TM) nebulizer is manufactured by Marquest, Englewood, Colorado. Letters and Roman
 
numerals in parentheses after regimens indicate the strength of the recommendation and the quality of evidence supporting it (see page 7).
 
ABBREVIATIONS: b.i.d. = twice a day; DS = double-strength tablet; po = by mouth; q.d. = daily; q.m. = monthly; q.w. = weekly; q.o.w. =
 
every other week; SS = single-strength tablet; t.i.d. = three times a day; t.i.w. = three times a week; and TMP-SMZ = trimethoprim-
sulfamethoxazole.
 




2Many multiple-drug regimens are poorly tolerated. Drug interactions (e.g., those seen with clarithromycin and rifabutin) can be problematic;
 
rifabutin has been associated with uveitis, especially when administered at daily doses of >300 mg or concurrently with fluconazole or
 
clarithromycin. See discussion of rifamycin interactions in paragraph 9 in section on Tuberculosis (54). During pregnancy, azithromycin is
 
recommended instead of clarithromycin because clarithromycin is teratogenic in animals.
 




                       
  
 
TABLE 3. Effects of Food on Drugs Used to Prevent Opportunistic Infections 
Drug Food Effect Recommendation 
Atovaquone Bioavailability increased up to 
threefold with high-fat meal. 
Ganciclovir (capsules) High-fat meal results in 22% 
(GCV) or 30% (VGCV) increase in AUC. 
Itraconazole Grapefruit juice results in 30% decrease 
in AUC. 
Itraconazole (capsules) Significant increase in bioavailability when taken 
with a full meal. 
Itraconazole (solution) 31% increase in AUC when taken under 
fasting conditions 
Administer with food. 
High fat meal may 




Administer with food. 
Take without 
food if possible. 
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TABLE 4. Effects of Medications on Drugs used to Prevent Opportunistic Infections 
Affected Drug Interacting Drug(s) Mechanism/Effect Recommendation 
Atovaquone Rifampin Induction of 
metabolism -
decreased drug levels 
Concentrations might 
not be therapeutic; 
avoid combination or 
increase atovaquone 
dose. 
Atovaquone Lopinavir-ritonavir Potential for induction of 
metabolism - decreased 
drug levels 
Concentrations may 
not be therapeutic -
may require increase 
atovaquone dose, but data 
insufficient to make 
specific recommendation. 
Clarithromycin Efavirenz Induction of metabolism -
decrease in clarithromycin 
AUC by 39%, increase in 





Clarithromycin Ritonavir Inhibition of metabolism – 
increased clarithromycin drug 
levels by 77% 
Dose adjustment of 
clarithromycin necessary 
only if renal dysfunction 
is present. For CrCl < 60 
ml/min, reduce 
clarithromycin dose by 
50% ; for CrCl <30 
ml/min, reduce dose by 
75%. 
Clarithromycin Lopinavir-Ritonavir Inhibition of metabolism -
increased clarithromycin 
drug levels 
Dose adjustment of 
clarithromycin necessary 
only if renal dysfunction 
is present. For CrCl < 60 
ml/min, reduce 
clarithromycin dose by 
50% ; for CrCl <30 
ml/min, reduce dose by 
75%. 
Clarithromycin Nevirapine Induction of metabolism -
decrease in 
clarithromycin AUC by 35%, 
increase in AUC of 14-OH 






Ketoconazole Lopinavir-ritonavir Inhibition of metabolism, 
increased ketoconazole AUC 
Use with caution 
at ketoconazole doses 
>200 mg/day 
Ketoconazole Antacids, didanosine, 




Increase in gastric pH 
that impairs absorption of 
ketoconazole 
Avoid use of 
ketoconazole with 








Didanosine, (but not didanosine EC) 




in marked decrease in 
quinolone drug levels 
Administer 
cation 
preparation at least 2 
hours after quinolone. 
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TABLE 4. Effects of Medications on Drugs used to Prevent Opportunistic Infections (continued)
 Affected Drug Interacting Drug(s) Mechanism/Effect Recommendation 
Rifabutin Fluconazole Inhibition of 
metabolism - marked 
increase in rifabutin 
drug levels 
Monitor for rifabutin 
toxicities such as 
uveitis, nausea, 
neutropenia. 
Rifabutin Efavirenz Induction of 
metabolism -
significant decrease in 
rifabutin AUC 
Increase rifabutin dose 
to 450-600 mg daily or 
600 mg twice weekly.* 
Rifabutin Ritonavir, lopinavir-ritonavir, 
ritonavir-saquinavir 
Inhibition of metabolism -
marked increase in rifabutin 
drug levels 
Decrease rifabutin to 
150 mg every other 
day or three times 
per week. 
Rifabutin Indinavir, nelfinavir, amprenavir Inhibition of metabolism -
marked increase in rifabutin 
drug levels 
Decrease rifabutin to 
150 mg qd or 300 mg 
three times per week. 




TABLE 5. Effects of Opportunistic infection Medications on Antiinfective Drugs Commonly 
Administered to Persons Infected with Human Immunodeficiency Virus*
 Affected Drug Interacting Drug(s) Mechanism/Effect Recommendation 
Amprenavir, Rifampin Induction of metabolism Avoid concomitant 
delavirdine,indinavir, -- marked decrease use. 
lopinavir-ritonavir, in protease inhibitor 
nelfinavir, saquinavir or delavirdine drug levels 
Efavirenz, ritonavir, Rifampin Induction of Combinations 
ritonavir-saquinavir, metabolism:  could possibly be 
nevirapine decrease in protease or used but limited 
nevirapine levels clinical experience. 
Consider efavirenz 
800 mg q.d. when used 
with rifampin 
Delavirdine Rifabutin Induction of metabolism - Avoid concomitant 
50-60% decrease in use 
delavirdine levels 
Indinavir, Rifabutin Induction of metabolism - Consider increase in 
nelfinavir, 50% decrease in indinavir dose to 
amprenavir* protease inhibitor levels 1000 mg q8h; 
If indinavir is the sole 
protease inhibitor 
decrease rifabutin 
dose to 150 mg q.d. 
Ritonavir, ritonavir- Rifabutin Induction of metabolism of No dosage change for 
saquinavir, lopinavir- ritonavir protease inhibitors. 
ritonavir Consider rifabutin 
150 mg q.o.d. or three 
times per week 
Efavirenz Rifabutin Potential for decreased efavirenz No dosage change 
levels necessary for 
efavirenz; adjust 
rifabutin dose to 450-
600 mg qd or 600 mg 
twice weekly. 
Saquinavir Rifabutin Potential for decreased saquinavir Limited data 
levels 
Didanosine Ganciclovir (po) Increased ddI AUC Clinical significance 
by approximately 100% unknown; monitor for 
ddI-related adverse 
effects. 
*Little data are available for use of rifamycin drugs with ritonavir-boosting protease inhibitor regimens except for ritonavir-saquinavir and 
ritonavir-lopinavir. Therefore, concomitant use of rifamycins with these regimens must be approached cautiously. 
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TABLE 6. Adverse Effects of Drugs Used in the Prevention of Opportunistic Infections 
Bone Marrow Suppression Cidofovir, dapsone, ganciclovir, pyrimethamine, rifabutin, sulfadiazine, 
TMP-SMX 
Diarrhea Atovaquone, clindamycin 
Hepatotoxicity Clarithromycin, fluconazole, isoniazid, itraconazole, ketoconazole, 
pyrazinamide, rifabutin, rifampin, TMP-SMX 
Nephrotoxicity Amphotericin B, cidofovir, foscarnet, pentamidine, high dose acyclovir 
Ocular Effects Cidofovir, ethambutol, rifabutin 
Pancreatitis Pentamidine, TMP-SMX 
Peripheral Neuropathy Isoniazid 
Neurotoxicity Acyclovir (high-dose), quinolones 
Skin Rash Atovaquone, dapsone, pyrimethamine, sulfadiazine, TMP-SMX, ribavirin 
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TABLE 7. Dosing of Drugs for Primary Prevention or Maintenance Therapy for Opportunistic 
Infections in Renal Insufficiency 
Drug Normal Dose Renal Dysfunction 
Acyclovir 200 mg - 800 mg BID -
5xday 
Regimen 
200 mg PO TID 





200 mg q12h 
200 mg q12h 
hemodialysis: additional dose after
 each dialysis 
Cidofovir 5 mg/kg IV every other 
week (with probenecid and 
hydration) 
Reduce from 5 mg/kg to 3 mg/kg for an increase in serum creatinine of 
0.3-0.4 above baseline. Discontinue for an increase in creatinine 0.5 
above baseline or development of 3+ proteinuria. 
Not recommended for patients with baseline serum creatinine 1.5, CrCl
 55 ml/min, or 2+ proteinuria 





250 mg-500 mg q 12 hrs 
250 mg-500 mg q 18 hrs 
250-500 mg after dialysis 
Clarithromycin 500 mg BID Reduce dose by one-half or double interval if creatinine clearance 
ml/min 
30 
Famciclovir 250-500 mg q 12 h CrCl Dose 
20-39 
20 
125-250 mg q 12 h 
125-250 mg q 24 h 
hemodialysis: 125 mg after each dialysis 
Fluconazole 50 mg - 400 mg qd CrCl 




Full dose after dialysis 
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TABLE 7. Dosing of Drugs for Primary Prevention or Maintenance Therapy for Opportunistic 
Infections in Renal Insufficiency – continued 
Foscarnet 90-120 mg/kg/day 
Ganciclovir Oral: 
1 gram TID (capsules) 
IV: 
5 mg/kg QD or 6 mg/kg QD
 5 days/week (IV) 
Levofloxacin 250 mg-500 mg QD 
TMP/SMX 1 DS QD 
1 DS TIW 
1 SS QD 
Valacyclovir 500 mg-1 gm q 24 h 































90 mg q 24h 
70 mg q 24 h 
50 mg q 24 h 
80 mg q 48 h 
60 mg q 48 h 
50 mg q 48 h 
not recommended 
High Dose 
120 mg q 24 h 
90 mg q 24 h 
65 mg q 24 h 
104 mg q 48h 
80 mg q 48 h 
65 mg q 48 h 
not recommended 
IV Dose (mg/kg) 
2.5 q 24 h 
1.25 q 24 h 
0.625 q 24 h 
0.625 TIW 
Capsules 
1500 mg qd or 500 mg tid 
1000 mg qd or 500 mg bid 
500 mb qd 
500 mg TIW after dialysis 
Dose 
500 mg LD, then 250 mg q 24 hrs 
500 mg LD, then 250 mg q 48 hrs 
Dose 
1/2 dose 
1/2 dose or use alternative agent 
Dose 
500 mg q 24-48 h 
Dose 
450 mg qd 
450 mg qd 
450 mg twice weekly 
not recommended 
not recommended 
ABBREVIATIONS: b.i.d. = twice daily; CrCl = creatinine clearance; DS = double-strength tablet; iv = intravenous; l.d. = loading
 
dose; q.d. = daily; q.o.w. = every other week; SS = single-strength tablet; t.i.d. = three times daily; t.i.w. =
 
three times a week.
 




TABLE 8. Wholesale Acquisition Costs of Agents Recommended for the Prevention of 
Opportunistic Infections in Adults Infected with Human Immunodeficiency Virus 
Opportunistic Annual Cost 
Pathogen Drug/Vaccine Dose Per Patient 
Pneumocystis carinii Trimethoprim- 160/800 mg q.d. $ 135 
Sulfamethoxazole 
Dapsone 100 mg q.d. $72 
Aerosolized pentamidine 300 mg q.m. $1,185 
Atovaquone 1500 mg q.d. $11,627 
Mycobacterium Clarithromycin 500 mg b.i.d. $ 2,843 
avium complex Azithromycin 1,200 mg q.w. $ 3,862 
Rifabutin 300 mg q.d. $3,352 
Cytomegalovirus Ganciclovir (po) 1,000 mg t.i.d. $17,794 
Ganciclovir implant* $5,000 
Ganciclovir (iv) 5mg/kg q.d. $13,093 
Foscarnet (iv) 90-120 mg/kg q.d. $27,770-37,027 
Cidofovir (iv) 375 mg q.o.w. $20,904 
Fomivirsen (intravitreal) 1 vial every 4 wks $12,000 
Valganciclovir 900 mg q.d. $21,582 
Mycobacterium Isoniazid† 300 mg q.d. $23 (9 months) 
tuberculosis Rifampin 600 mg q.d. $294 (2 months) 
Pyrazinamide 1,500 mg q.d. $194 (2 months) 
Fungi 	 Fluconazole 200 mg q.d. $4,603 
Itraconazole capsules 200 mg q.d. $5,340 
Itraconazole solution 200 mg q.d. $5,673 
Ketoconazole 200 mg q.d. $1,230 
Herpes simplex virus	 Acyclovir 400 mg b.i.d. $1,384 
Famciclovir 500 mg b.i.d. $5,311 
Valacyclovir 500 mg b.i.d. $2,538 
Toxoplasma gondii	 Pyrimethamine 50 mg q.w. $ 49 
Leucovorin 25 mg q.w. $ 988 
Sulfadiazine 500 mg q.i.d. $1,490 
Streptococcus 23-valent pneumococcal 0.5 ml im x 1 $13 
pneumoniae vaccine 
Influenza virus	 Inactivated trivalent 0.5 ml im x 1 $ 3 
influenza vaccine 
Hepatitis A virus	 Hepatitis A vaccine 1.0 ml im x 2 $ 124 
Hepatitis B virus	 Recombinant hepatitis B 10-20µg im x 3 $70 
Bacterial infections	 G-CSF 300 µg t.i.w. $29,406 
Varicella zoster virus	 VZIG 5 vials (6.25 ml) $ 562 
ABBREVIATIONS: b.i.d. = twice daily; G-CSF = granulocyte-colony-stimulating factor; iv = intravenous; im = intramuscular; po = by mouth; q.d. = 
daily; q.o.w. = every other week; q.w. = once a week; ; t.i.d. = three times daily; t.i.w. = three times a week; VZIG = varicella zoster immune globulin. 
*Implant generally lasts 6-9 months. 
†Cost for 9 months of therapy. 
Source: Medical Economics. Drug topics red book. Montvale, New Jersey: Medical Economics Inc., 2000. 
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TABLE 9. Immunologic Categories for Human Immunodeficiency Virus-infected Children Based on 









 1. No evidence of suppression 
2. Evidence of moderate
 suppression 










*Adapted from CDC. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 
1994;43(No. RR-12). (123). 
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Pertussis2 DTaP DTaP DTaP DTaP 
Haemophilus 
influenzae type b3 
Hib Hib Hib 
Inactivated Polio4 IPV IPV IPV 
Hepatitis A5 
Recommendations for these vaccines differ from those for immunocompetent children. 




Varicella8 Var Var 
Influenza9 
Hep B #1 








Do not give to severely immuno-
suppressed (Category 3) children 
MMR 
Give only to asymptomatic non-
immunosuppressed (category 1) 
children. Contraindicated in all other 
HIV infected children. 




(age 5-7 yrs) 
Range of recommended ages for vaccination. 
Vaccines to be given if previously recommended doses were missed or were given earlier 
than the recommended minimum age. 
Recommended in selected states and/or regions. 
This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines as of November 1, 2000, for 
children through age 18 years. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be 
used whenever any components of the combination are indicated and the vaccine’s other components are not contraindicated. Providers should 
consult the manufacturer’s package inserts for detailed recommendations. 
1. Infants born to hepatitis B surface antigen (HBsAg)- negative mothers should receive the first dose of hepatitis B vaccine (Hep B) at 
birth and no later than age 2 months. The second dose should be administered at least 1 month after the first dose. The third dose should be 
administered at least 4 months after the first dose and at least 2 months after the second dose, but not before age 6 months. Infants born to 
HBsAg- positive mothers should receive Hep B and 0.5 mL hepatitis B immune globulin (HBIG) within 12 hours of birth at separate sites. The 
second dose is recommended at age 1– 2 months and the third dose at age 6 months. Infants born to mothers whose HBsAg status is unknown 
should receive Hep B within 12 hours of birth. Maternal blood should be drawn at delivery to determine the mother’s HBsAg status; if the HBsAg 
test is positive, the infant should receive HBIG as soon as possible (no later than age 1 week). All children and adolescents (through age 18 
years) who have not been immunized against hepatitis B should begin the series during any visit. Providers should make special efforts to 
immunize children who were born in or whose parents were born in areas of the world where hepatitis B virus infection is moderately or highly 
endemic. 
2. The fourth dose of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) may be administered as early as age 12 months, 




is recommended at age 11– 12 years if at least 5 years have elapsed since the last dose of diphtheria and tetanus toxoids and pertussis vaccine 
(DTP), DTaP, or diphtheria and tetanus toxoids (DT). Subsequent routine Td boosters are recommended every 10 years. 
3. Three Haemophilus influenzae type b (Hib) conjugate vaccines are licensed for infant use. If Hib conjugate vaccine (PRP- OMP) (PedvaxHIB 
or ComVax [Merck]) is administered at ages 2 and 4 months, a dose at age 6 months is not required. Because clinical studies in infants have 
demonstrated that using some combination products may induce a lower immune response to the Hib vaccine component, DTaP/ Hib combination 
products should not be used for primary immunization in infants at ages 2, 4 or 6 months unless approved by the Food and Drug Administration 
for these ages. 
4. An all- inactivated poliovirus vaccine (IPV) schedule is recommended for routine childhood polio vaccination in the United States. All 
children should receive four doses of IPV at age 2 months, age 4 months, between ages 6 and 18 months, and between ages 4 and 6 years. Oral 
poliovirus vaccine should not be administered to HIV infected persons or their household contacts. 
5. 5. Hepatitis A vaccine (Hep A) is recommended for use in selected states and/ or regions, and for certain high- risk groups such as those with 
Hepatitis B or Hepatitis C infection. Information is available from local public health authorities. 
6. The heptavalent pneumococcal conjugate vaccine (PCV) is recommended for all children age 2-59 months with HIV. Children 2 
years and older should also receive the 23 valent pneumococcal polysaccharide vaccine; a single revaccination with the 23 valent vaccine 
should be offered to children after 3-5 years. Refer to the Advisory Committee on Immunization Practices recommendations (80) on 
dosing intervals for children starting the vaccination schedule after 2 months of age. 
7. MMR should not be administered to severely immunocompromised (category 3) children. HIV infected children without severe 
immunosuppression would routinely receive their first dose of MMR as soon as possible after reaching their first birthday. Consideration should 
be given to administering the second dose of MMR as soon as 1 month (i.e., a minimum of 28 days) after the first dose rather then waiting until 
school entry. 
8. Varicella zoster virus vaccine should be given only to asymptomatic, nonimmunosuppressed children. Eligible children should receive 
two doses of vaccine with at least a 3-month interval between doses. The first dose may be given as early as 12 months of age. 
9. Inactivated split influenza virus vaccine should be administered to all HIV infected children 6 months of age each year. 
For children aged 6 months to <9 years who are receiving influenza vaccine for the first time, two doses given 1 month apart are 
recommended. For specific recommendations, see: CDC. Prevention and Control of Influenza: Recommendations of the Advisory 





   
 
 
    
 
 
TABLE 11. Prophylaxis to Prevent First Episode of Opportunistic Disease in Infants and Children 
Infected with Human Immunodeficiency Virus 
Preventive Regimens 
Pathogen	 Indication First Choice Alternatives










Varicella zoster virus3 
HIV-infected or 
HIV-indeterminate, 
infants aged 1-12 mo; 
HIV-infected children 
aged 1-5 yr with CD4+ 
count <500/µL or CD4+ 
percentage <15%; 
HIV-infected children 
aged 6-12 yr with 














regardless of TST result
Same as above; high 
probability of exposure 
to isoniazid-resistant 
tuberculosis 
Same as above; high 
probability of exposure 
to multi-drug resistant 
tuberculosis 
For children aged 
>6 yrs, CD4+ count 
<50/µL; aged 2-6 yrs 
CD4+ count <75/µL; 
aged 1-2 yrs, CD4+ 
count <500/µL; aged 




to varicella or shingles
 




Trimethoprim- Dapsone (children 
sulfamethoxazole aged >1 mo), 2mg/kg 
(TMP-SMZ), 150/750 (max 100 mg) po q.d. 
mg/m2/d in 2 divided or 4 mg/kg (max 
doses po t.i.w. 200 mg) po q.w. (CII); 
on consecutive days (AII) aerosolized 
pentamidine (children 
Acceptable alternative aged >5 yr), 300 mg 
dosage schedules: (AII) q.m. via Respirgard 
IITM nebulizer 
•Single dose po	 (CIII); atovaquone 
t.i.w. on	 (children aged 1-3 mo. 
consecutive days;	 and >24 mo., 30mg/kg
 
po q.d.; children aged
 
•2 divided doses po	 4-24 mo., 45 mg/kg po
 q.d.; 2 divided doses q.d.) (CII)
 po t.i.w. on alternate
 days 
Isoniazid 10-15 mg/kg Rifampin,
 
(max 300 mg) po q.d. x 10-20 mg/kg (max
 
9 mo (AII) or 600 mg) po q.d. x 4-6 mo
 
20-30 mg/kg (max (BIII)
 





mg/kg (max 600 mg) 
po q.d. x 4-6 mo (BIII) 
Choice of drugs 
requires consultation 
with public helath 
authorities and 
depends on 
susceptibility of isolate 
from source patient 
Clarithromycin	 Azithromycin, 5 mg/kg 
7.5 mg/kg (max (max 250 mg) po q.d. 
500 mg) po b.i.d. (AII), (AII); children aged 
or azithromycin, >6 yrs, rifabutin, 
20 mg/kg (max 300 mg po q.d. (BI) 
1,200 mg) po q.w. (AII) 
Varicella zoster None 
immune globulin 
(VZIG), 1 vial 
(1.25 mL)/10 kg (max 
5 vials) im, administered 
<96 hrs after exposure, ideally 












TABLE 11. Prophylaxis to Prevent First Episode of Opportunistic Disease in Infants and Children 
Infected with Human Immunodeficiency Virus - continued 
Preventive Regimens 
Pathogen	 Indication First Choice Alternatives 
Vaccine-preventable HIV exposure/infection Routine None 
Pathogens4 immunizations 
(see Table 10) 
II. Generally recommended 
Toxoplasma gondii5	 IgG antibody to TMP-SMZ, Dapsone (children 
Toxoplasma 150/750 mg/m2/d in 2 aged >1 mo), 2mg/kg 
and severe divided doses po q.d. or 15 mg/m2 (max 
immunosuppression (BIII) 25 mg) po q.d. plus 
pyrimethamine, 
1 mg/kg po q.d. plus 
leucovorin, 5 mg po 
every 3 days (BIII) 
Atovaquone, (aged 
1-3 mo. and >24 mo., 
30 mg/kg po q.d.; 
aged 14-24 mo. 
45 mg/kg po q.d.) 
(CIII) 
Varicella zoster virus	 HIV-infected children Varicella zoster None 
who are vaccine (see vaccine-
asymptomatic and not preventable pathogens 
immunosuppressed section of this table) 
(BII) 
Influenza virus	 All patients (annually, Inactivated split Oseltamivir (during
before influenza trivalent  influenza outbreaks of influenza 
season) vaccine (see vaccine- A or B) for children 
preventable  13 years, 75 mg po q.d. 
section of this table) (CIII); rimantadine or 
(BIII) amantadine (during 
outbreaks of influenza 
A); aged 1-9 yr, 
5 mg/kg in 2 divided 
doses (max 150 mg/day) 
po q.d.; aged 
>10 yr, use adult 
doses (CIII). 
III. Not recommended for most children; indicated for use only in unusual circumstances 
Invasive bacterial Hypogamma- IVIG (400mg/kg every None 
infections6 globulinemia (i.e., IgG 2-4 wks) (AI) 
<400 mg/dL) 
Cryptococcus Severe Fluconazole, 3-6 Itraconazole, 
neoformans immunosuppression mg/kg po q.d. (CII) 2-5 mg/kg po every 
12-24 h (CII) 
Histoplasma	 Severe Itraconazole, None 
capsulatum	 immunosuppression, 2-5 mg/kg po every 
endemic geographic 12-24 h (CIII) 
area 
Cytomegalovirus CMV antibody Oral ganciclovir None 
(CMV)7 positivity and severe 30 mg/kg po t.i.d. (CII) 
immunosuppression 
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NOTES: Information included in these guidelines might not represent Food and Drug Administration (FDA) approval or 
approved labeling for the particular products or indications in question. Specifically, the terms "safe" and "effective" might not be 
synonymous with the FDA-defined legal standards for product approval. The Respirgard IITM nebulizer is manufactured by 
Marquest, Englewood, Colorado. Letters and Roman numerals in parentheses after regimens indicate the strength of the 
recommendation and the quality of the evidence supporting it (see page 7). 
ABBREVIATIONS: b.i.w. = twice a week; IVIG = intravenous immune globulin; q.d. = daily; q.m. = monthly; t.i.d. = three 
times a day; t.i.w. = three times a week. 
1Daily TMP-SMZ reduces the frequency of some bacterial infections. TMP-SMZ, dapsone-pyrimethamine, 
and possibly atovaquone (with or without pyrimethamine) appear to protect against toxoplasmosis, although data have not been 
prospectively collected. When compared with weekly dapsone, daily dapsone is associated with lower incidence of Pneumocystis 
carinii  pneumonia (PCP) but higher hematologic toxicity and mortality (McIntosh K, Cooper E, Xu J, et al. Toxicity and Efficacy 
of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with HIV. Ped Infect Dis J 
1999;18:432-9). 
The efficacy of parenteral pentamidine (e.g., 4 mg/kg q 2-4 wks) is controversial. Patients receiving therapy for toxoplasmosis with 
sulfadiazine-pyrimethamine are protected against PCP and do not need TMP-SMZ. 
2Significant drug interactions can occur between rifamycins (rifampin and rifabutin) and protease inhibitors and 
nonnucleoside reverse transcriptase inhibitors. Consult a specialist. 
3Children routinely being administered intravenous immune globulin (IVIG) should receive VZIG if the last dose of IVIG was 
administered >21 days before exposure. 
4HIV-infected and HIV-exposed children should be immunized according to the childhood immunization schedule in this 
report (Table 10), which has been adapted from the January-December 2001 schedule recommended for immunocompetent 
children by the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, and the American 
Academy of Family Physicians. This schedule differs from that for immunocompetent children in that both the conjugate 
pneumococcal vaccine (PCV-7) and the pneumococcal polysaccharide vaccine (PPV-23) are recommended (BII) and 
vaccination against influenza (BIII) should be offered. MMR should not be administered to severely immunocompromised children 
(DIII). Vaccination against varicella is indicated only for asymptomatic nonimmunosuppressed children (BII). Once an HIV-exposed 
child is determined not to be HIV infected, the schedule for immunocompetent children applies. 
5Protection against toxoplasmosis is provided by the preferred antipneumocystis regimens and possibly by atovaquone. 
Atovaquone may be used with or without pyrimethamine. Pyrimethamine alone probably provides little, if any, protection (for 
definition of severe immunosuppression, see Table 9). 
6Respiratory syncytial virus (RSV) IVIG (750 mg/kg), not monoclonal RSV antibody, may be substituted for IVIG during the 
RSV season to provide broad antiinfective protection, if this product is available. 













TABLE 12. Prophylaxis to Prevent Recurrence of Opportunistic Disease (after chemotherapy for acute 
disease) in HIV-infected Infants and Children 
Preventive Regimens
 Pathogen Indication First Choice Alternatives 
I. Recommended for life as standard of care 
Pneumocystis carinii Prior P. carinii 
pneumonia 
TMP-SMZ, 150/750 
mg/m2/d in 2 divided 
Dapsone (children 
aged >1 mo), 2 
doses po t.i.w. on mg/kg 
consecutive days (AII) (max 100 mg) po q.d. 
or 4 mg/kg (max 
Acceptable alternative 200 mg) po q.w. (CII); 
schedules for same aerosolized pentamidine (children 
dosage: (AII) aged >5 yrs), 300 mg 
q.m. via Respirgard IITM 
Single dose po t.i.w. on nebulizer (CIII); 
consecutive days; atovaquone (aged 1-3 months 
2 divided doses po q.d; and >24 mo., 30 mg/kg po 
2 divided doses po q.d.; aged 4-24 mo., 45 mg/kg po 
t.i.w. on alternate days q.d.) (CII) 
Toxoplasma gondii1 Prior toxoplasmic Sulfadiazine, Clindamycin, 
encephalitis 85-120 mg/kg/d in 20-30 mg/kg/d in 
2-4 divided doses po 4 divided doses po q.d. 
q.d. plus 
pyrimethamine, 
1 mg/kg or 15 mg/m2 
plus pyrimethamine, 
1 mg/kg po q.d. plus 
leucovorin, 5 mg po 
(max 25 mg) po q.d. every 3 days (BI) 
plus leucovorin, 5 mg 
po every 3 days (AI) 
Mycobacterium avium 
Complex2 
Prior disease Clarithromycin, 
7.5 mg/kg (max 
500 mg) po b.i.d. (AII) 
Azithromycin, 5 mg/kg 
(max 250 mg) po q.d. 
(AII) plus ethambutol, 
plus ethambutol, 15 mg/kg (max 
15 mg/kg (max 900 mg) po q.d. (AII); 
900 mg) po q.d. (AII); with or without 
with or without rifabutin, 5 mg/kg (max 
rifabutin, 5 mg/kg (max 300 mg) po q.d. (CII) 
300 mg) po q.d. (CII) 
Cryptococcus Documented disease Fluconazole, 3-6 mg/kg Amphotericin B, 
neoformans po q.d. (AII) 0.5-1.0 mg/kg iv 
1-3x/week (AI); 
itraconazole, 2-5 
mg/kg po every 12-24h 
(BII). 
Histoplasma Documented disease Itraconazole, Amphotericin B, 
capsulatum 2-5 mg/kg po every 1.0 mg/kg iv q.w. (AIII) 
12-48 h (AIII) 
Coccidioides immitis Documented disease Fluconazole, 6 mg/kg Amphotericin B, 
po q.d. (AIII) 1.0 mg/kg iv q.w. (AIII); 
itraconazole, 2-5 mg/kg 
po every 12-48 h (AIII) 
Cytomegalovirus Prior end-organ Ganciclovir, 5 mg/kg iv (For retinitis) 
disease q.d.; or foscarnet, Ganciclovir 
90-120 mg/kg iv q.d. sustained-release 
(AI) implant every 6-9 mo. 
Plus ganciclovir, 30 mg/kg 
po t.i.d. (BIII) 
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TABLE 12. Prophylaxis to Prevent Recurrence of Opportunistic Disease (after chemotherapy for acute 
disease) in HIV-infected Infants and Children - continued 
Preventive Regimens
 Pathogen	 Indication First Choice Alternatives 
Salmonella species Bacteremia	 TMP-SMZ, Antibiotic 
(non-typhi)3	 150/750 mg/m2 in chemoprophylaxis 
2 divided doses po q.d. with another active 
for several months (CIII) agent (CIII) 
II. Recommended only if subsequent episodes are frequent or severe 
Invasive bacterial >2 infections in	 TMP-SMZ, Antibiotic 
Infections4 1-year period	 150/750 mg/m2, in chemoprophylaxis 
2 divided doses po q.d. with another active 
(BI); or IVIG, 400 mg/kg agent (BIII) 
every 2-4 wks. (BI) 
Herpes simplex virus Frequent/severe Acyclovir, 80 mg/kg/d 
recurrences in 3-4 divided doses 
po q.d. (AII) 
Candida Frequent/severe Fluconazole, 3-6 mg/kg 
(oropharyngeal) recurrences po q.d. (CIII) 
Candida (esophageal)	 Frequent/severe Fluconazole, 3-6 mg/kg Itraconazole solution, 
recurrences po q.d. (BIII) 5 mg/kg po q.d. (CIII); 
NOTES: Information included in these guidelines might not represent Food and Drug Administration (FDA) approval or approved 
labeling for the particular products or indications in question. Specifically, the terms "safe" and "effective" might not be synonymous 
with the FDA-defined legal standards for product approval. The Respirgard IITM nebulizer is manufactured by Marquest, Englewood, 
Colorado. Letters and Roman numerals in parentheses after regimens indicate the strength of the recommendations and the quality of 
evidence supporting it (see page 7). 
ABBREVIATIONS: IVIG = intravenous immune globulin; po = by mouth; q.d. = daily; q.m. = monthly; q.w. = weekly; t.i.d. = three 
times a day; t.i.w. = three times a week; and TMP-SMZ = trimethoprim-sulfamethoxazole. 
1Only pyrimethamine plus sulfadiazine confers protection against PCP as well as toxoplasmosis. Although the clindamycin plus 
pyrimethamine regimen is recommended in adults, it has not been tested in children. However, these drugs are safe and are used for 
other infections. 
2Significant drug interactions might occur between rifabutin and protease inhibitors and nonnucleoside reverse transcriptase inhibitors. 
Consult an expert. 
3Drug should be determined by susceptibilities of the organism isolated. Alternatives to TMP-SMZ include ampicillin, 
chloramphenicol, or ciprofloxacin. However, ciprofloxacin is not approved for use in persons aged <18 years; therefore, it should be 
used in children with caution and only if no alternatives exist. 
4Antimicrobial prophylaxis should be chosen based on the microorganism and antibiotic sensitivities. TMP-SMZ, if used, should be 
administered daily. Providers should be cautious about using antibiotics solely for this purpose because of the potential for 
development of drug-resistant microorganisms. IVIG might not provide additional benefit to children receiving daily TMP-SMZ but 
may be considered for children who have recurrent bacterial infections despite TMP-SMZ prophylaxis. Choice of antibiotic 
prophylaxis vs. IVIG should also involve consideration of adherence, ease of intravenous access, and cost. If IVIG is used, 
respiratory syncytial virus (RSV) IVIG (750 mg/kg), not monoclonal RSV antibody, may be substituted for IVIG during the RSV 
season to provide broad anti-infective protection, if this product is available. 
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 Table 13. Criteria for Starting, Discontinuing, and Restarting Opportunistic Infection Prophylaxis for Adults with human Immunodeficiency Virus Infection* 
Criteria for Initiating Criteria for Criteria for Criteria for Initiating Criteria for Criteria for 
Primary Prophylaxis Discontinuing Restarting Primary Secondary Discontinuing Restarting 
Primary Prophylaxis Prophylaxis Prophylaxis Secondary Prophylaxis Secondary 
Prophylaxis 
Opportunistic Illness 
Pneumocystis carinii CD4+ <200 cells/µL CD4+ >200 cells/µL CD4+ <200 cells/µL Prior Pneumocystis CD4+ >200 cells/µL for CD4+ <200 cells/µL 
pneumonia or oropharyngeal for 3 months (AI) (AIII) carinii pneumonia 3 months (BII) (AIII) 
cadidiasis (AI) (AI) 
Toxoplasmosis IgG antibody to CD4+ >200 cells/µL CD4+ <100-200 Prior toxoplasmic •CD4+ >200 cells/µL CD4+<200 cells/µL 
toxoplasma and for 3 months (AI) cells/µL (AIII) encephalitis (AI) sustained (e.g., 6 (AIII) 





•Asymptomatic for toxo 
(CIII) 
Disseminated CD4+ <50 cells/µL CD4+ >100 cells/µL CD4+ <50-100 Documented •CD4+ >100 cells/µL CD4+ <100 cells/µL 
Mycobacterium avium (AI) for 3 months (AI) cells/µL (AIII) disseminated disease sustained (e.g., 6 (AIII) 
complex (AII) months) and 
*Completed 12 months 
of MAC therapy and 
*Asymptomatic for 
MAC (CIII) 
Cryptococcosis None Not applicable Not applicable Documented disease •CD4+ >100-200 CD4+ <100-200 
(AI) cells/µL sustained (e.g., cells/µL (AIII) 





Histoplasmosis None Not applicable Not applicable Documented disease No criteria Not applicable 
(AI) recommended for 
stopping 
Coccidioidomycosis None Not applicable Not applicable Documented disease No criteria Not applicable 
(AI) recommended for 
stopping 
Cytomegalovirus None Not applicable Not applicable Documented end- •CD4+ >100-150 CD4+<100-150 
retinitis organ disease (AI) cells/µL sustained (e.g., cells/µL (AIII) 
6 months) and 
• No evidence of active 
disease 








APPENDIX. Recommendations to Help Patients Avoid
 
Exposure to or Infection with Opportunistic Pathogens*
 
SEXUAL EXPOSURES 
1. Patients should use a latex condom during every act of sexual intercourse to reduce the risk for acquiring 
cytomegalovirus, herpes simplex virus, and human papil-lomavirus, as well as other sexually transmitted pathogens 
(AII). Condom use also will, theoretically, reduce the risk for acquiring human herpesvirus 8, as well as super-
infection with an HIV strain that has become resistant to antiretroviral drugs (BIII) and will prevent transmission of 
HIV and other sexually transmitted pathogens to others (AII). Data regarding the use and efficacy of female 
condoms are incomplete, but these devices should be considered as a risk-reduction strategy (BIII). 
2. Patients should avoid sexual practices that might result in oral exposure to feces (e.g., oral-anal contact) to 
reduce the risk for intestinal infections (e.g., cryptosporidiosis, shigellosis, campylobacteriosis, amebiasis, giardiasis, 
and hepatitis A (BIII).  Latex condom use alone may not reduce the risk of acquiring these fecal-orally 
transmitted pathogens, especially those which have low infectious doses. Persons wishing to reduce their risk 
of exposure might consider using dental dams or similar barrier methods for oral-anal and oral-genital 
contact, changing condoms after anal intercourse, and wearing latex gloves during digital-anal contact. 
Frequently washing hands and genitals with warm soapy water during and after activities which may bring 
these body parts in contact with feces may further reduce risk of illness. (CIII). 
3. Hepatitis B immunizations is recommended for all susceptible (anti-HBc-negative) HIV-infected 
patients (BII). 
4. Hepatitis A immunization is recommended for all susceptible men who have sex with men, as well as 
others with indications for HAV vaccine (BIII). 
INJECTION DRUG USE EXPOSURES 
1. Injection drug use is a complex behavior that puts HIV-infected persons at risk for hepatitis B virus and 
hepatitis C virus infection, additional, possibly drug-resistant strains of HIV, and other blood-borne pathogens. 
Providers should assess the individual’s readiness to change this practice and encourage efforts to provide education 
and support directed at recovery. Patients should be counseled to stop using injection drugs (AIII) and to enter and 
complete substance-abuse treatment, including relapse prevention programs 
(AIII). 
2. If they are continuing to inject drugs, patients should be advised (BIII) 
•	 to never reuse or share syringes, needles, water, or drug preparation equipment; if, nonetheless, injection 
equipment that has been used by other persons is shared, to first clean the equipment with bleach and water 
(U.S. Public Health Service. HIV prevention bulletin: medical advice for persons who inject illicit drugs. 
May 8, 1997. Rockville, Maryland: CDC, 1997); 




•	 to use sterile (e.g., boiled) water to prepare drugs; if not possible, to use clean water from a reliable
 
source (e.g., fresh tap water); to use a new or disinfected container (“cooker”) and a new filter
 
(“cotton”) to prepare drugs;
 
•	 to clean the injection site with a new alcohol swab before injection; 
•	 to safely dispose of syringes after one use. 
3. All susceptible injection drug users should be immunized against hepatitis B (BII) and hepatitis A (BIII). 
*Letters and Roman numerals in parentheses indicate the strength of the recommendation and the quality of evidence supporting 
it (see Box, page 3). 
ENVIRONMENTAL AND OCCUPATIONAL EXPOSURES 
1. Certain activities or types of employment might increase the risk for exposure to tuberculosis (BIII). 
These include volunteer work or employment in health-care facilities, correctional institutions, and shelters for the 
homeless, as well as other settings identified as high risk by local health authorities. Decisions about whether to 
continue with such activities should be made in conjunction with the health-care provider and should be based on 
such factors as the patient’s specific duties in the workplace, the prevalence of tuberculosis in the community, and 
the degree to which precautions designed to prevent the transmission of tuberculosis are taken in the workplace 
(BIII). These decisions will affect the frequency with which the patient should be screened for tuberculosis. 
2. Child-care providers and parents of children in child care are at increased risk for acquiring CMV 
infection, cryptosporidiosis, and other infections (e.g., hepatitis A and giardiasis) from children. The risk for 
acquiring infection can be diminished by good hygienic practices, such as hand washing after fecal contact (e.g., 
during diaper changing) and after contact with urine or saliva (AII). All children in child-care facilities also are at 
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increased risk for acquiring these same infections; parents and other caretakers of HIV-infected children should be 
advised of this risk (BIII). 
3. Occupations involving contact with animals (e.g., veterinary work and employment in pet stores, farms, 
or slaughterhouses) might pose a risk for cryptosporidiosis,toxoplasmosis, salmonellosis, campylobacteriosis, or 
Bartonella infection. However, the available data are insufficient to justify a recommendation against work in such 
settings. 
4. Contact with young farm animals, especially animals with diarrhea, should be avoided to reduce the risk 
for cryptosporidiosis (BII). 
5. Hand washing after gardening or other contact with soil might reduce the risk for cryptosporidiosis and 
toxoplasmosis (BIII). 
6. In areas endemic for histoplasmosis, patients should avoid activities known to be associated with 
increased risk (e.g., creating dust when working with surface soil; cleaning chicken coops that are heavily 
contaminated with compost droppings; disturbing soil beneath bird-roosting sites; cleaning, remodeling or 
demolishing old buildings; and cave exploring) (CIII). 
7. In areas endemic for coccidioidomycosis, when possible, patients should avoid activities associated with 
increased risk, including those involving extensive exposure to disturbed native soil (e.g., at building excavation 
sites or during dust storms) (CIII). 
PET-RELATED EXPOSURES 
Health-care providers should advise HIV-infected persons of the potential risk posed by pet ownership. 
However, they should be sensitive to the possible psychological benefits of pet ownership and should not routinely 
advise HIV-infected persons to part with their pets (DIII). Specifically, providers should advise HIV-infected 
patients of the following precautions. 62 MMWR August 20, 1999 
General 
1. Veterinary care should be sought when a pet develops diarrheal illness. If possible, HIV-infected persons 
should avoid contact with animals that have diarrhea (BIII). A fecal sample should be obtained from animals with 
diarrhea and examined for Cryptosporidium, Salmonella, and Campylobacter. 
2. When obtaining a new pet, HIV-infected patients should avoid animals aged <6 months (or < 1 year for 
cats; see Cats section, which follows), especially those with diarrhea (BIII). Because the hygienic and sanitary 
conditions in pet-breeding facilities, pet stores, and animal shelters are highly variable, the patient should be 
cautious when obtaining a pet from these sources. Stray animals should be avoided. Animals aged <6 months, 
especially those with diarrhea, should be examined by a veterinarian for Cryptosporidium, Salmonella, and 
Campylobacter (BIII). 
3. Patients should wash their hands after handling pets (especially before eating) and avoid contact with 
pets’ feces to reduce the risk for cryptosporidiosis, salmonellosis, and campylobacteriosis (BIII). Hand washing for 
HIV-infected children should be supervised. 
Cats 
4. Patients should be aware that cat ownership increases their risk for toxoplasmosis and Bartonella 
infection, as well as enteric infections (CIII). Those who elect to obtain a cat should adopt or purchase an animal 
that is aged >1 year and in good health to reduce the risk for cryptosporidiosis, Bartonella infection, salmonellosis, 
and campylobacteriosis (BII). 
5. Litter boxes should be cleaned daily, preferably by an HIV-negative, nonpregnant person; if the HIV-
infected patient performs this task, he or she should wash hands thoroughly afterward to reduce the risk for 
toxoplasmosis (BIII). 
6. To reduce the risk for toxoplasmosis, HIV-infected patients should keep cats indoors, not allow them to 
hunt, and not feed them raw or undercooked meat (BIII). 
7. Although declawing is not generally advised, patients should avoid activities that might result in cat 
scratches or bites to reduce the risk for Bartonella infection (BII). Patients should also wash sites of cat scratches or 
bites promptly (CIII) and should not allow cats to lick the patients’ open cuts or wounds (BIII). 
8. Care of cats should include flea control to reduce the risk for Bartonella infection (CIII). 
9. Testing cats for toxoplasmosis (EII) or Bartonella infection (DII) is not recommended. 
Birds 
10. Screening healthy birds for Cryptococcus neoformans, Mycobacterium avium, or Histoplasma 
capsulatum is not recommended (DIII). 
62 
Other 
11. Contact with reptiles (e.g., snakes, lizards, iguanas, and turtles) as well as chicks and ducklings should 
be avoided to reduce the risk for salmonellosis (BIII). 
12. Gloves should be used during the cleaning of aquariums to reduce the risk for infection with 
Mycobacterium marinum (BIII). 
13. Contact with exotic pets (e.g., nonhuman primates) should be avoided (CIII). 
FOOD AND WATER-RELATED EXPOSURES 
1. Raw or undercooked eggs (including foods that might contain raw eggs [e.g., some preparations of 
hollandaise sauce, Caesar and certain other salad dressings, some mayonnaises, uncooked cookie and cake batter, 
egg nog]); raw or undercooked poultry, meat, seafood (especially raw shellfish); and unpasteurized dairy products; 
unpasteurized fruit juice; and raw seed sprouts (e.g., alfalfa sprouts, mung bean sprouts). Poultry and meat 
are safest when adequate cooking is confirmed with a thermometer (internal temperature of 180  F for 
poultry and 165  F for red meats). If a thermometer is not used, the risk of illness is decreased by consuming 
poultry and meat that have no trace of pink. Color change of the meat (e.g., absence of pink) does not always 
correlate with internal temperature. Produce should be washed thoroughly before being eaten (BIII). 
2. Cross-contamination of foods should be avoided. Uncooked meats should not be allowed to come in 
contact with other foods; hands, cutting boards, counters, and knives and other utensils should be washed thoroughly 
after contact with uncooked foods (BIII). 
3. Although the incidence of listeriosis is low, it is a serious disease that occurs unusually frequently among 
HIV-infected persons who are severely immunosuppressed. An immunosuppressed, HIV-infected person who 
wishes to reduce the risk of acquiring listeriosis as much as possible may choose to do the following: 
1) avoid soft cheeses (e.g., feta, Brie, Camembert, blue-veined and Mexican-style cheese such as queso fresco). 
Hard cheeses, processed cheeses, cream cheese (including slices and spreads), cottage cheese, or yogurt need 
not be avoided; 
2) cook leftover foods or ready-to-eat foods (e.g., hot dogs) until steaming hot before eating; 
3) avoid foods from delicatessen counters (e.g., prepared salads, meats, cheeses) or heat/reheat these foods 
until steaming before eating; 
4) avoid refrigerated pates and other meat spreads, or heat/reheat these foods until steaming if eaten. 
Canned or shelf-stable pate and meat spreads need not be avoided; 
5)avoid raw or unpasteurized milk (including goat’s milk) or milk-products, or foods which contain 
unpasteurized milk or milk-products. (CIII). 
4. Patients should not drink water directly from lakes or rivers because of the risk for cryptosporidiosis and 
giardiasis (AIII). Waterborne infection might also result from swallowing water during recreational activities. 
Patients should avoid swimming in water that is likely to be contaminated with human or animal waste and should 
avoid swallowing water during swimming (BII). 
5. During outbreaks or in other situations in which a community “boil water advisory” is issued, boiling 
water for 1 minute will eliminate the risk for acquiring cryptosporidiosis (AI). Using submicron, personal-use water 
filters (home/office types) and/or drinking bottled water might also reduce the risk (see Cryptosporidiosis section in 
Disease-Specific Recommendations for information on personal-use filters and bottled water) (CIII). Current data 
are inadequate to support a recommendation that all HIV-infected persons boil or otherwise avoid drinking tap water 
in nonoutbreak settings. However, persons who wish to take independent action to reduce their risk for waterborne 
cryptosporidiosis may choose to take precautions similar to those recommended during outbreaks. Such decisions 
are best made in conjunction with a health-care provider. Persons who opt for a personal-use filter or bottled water 
should be aware of the complexities involved in selecting the appropriate products, the lack of enforceable standards 
for destruction or removal of oocysts, the cost of the products, and the difficulty of using these products consistently. 
Patients taking precautions to avoid acquiring cryptosporidiosis from drinking water should be advised that ice made 
from contaminated tap water also can be a source of infection (BII). Such persons should be aware that fountain 
beverages served in restaurants, bars, theaters, and other public places might also pose a risk, because these bever-
ages, as well as the ice they might contain, are made from tap water. Nationally distributed brands of bottled or 
canned carbonated soft drinks are safe to drink. Commercially packaged noncarbonated soft drinks and fruit juices 
that do not require refrigeration until after they are opened (i.e., those that can be stored unrefrigerated on grocery 
shelves) also are safe. Nationally distributed brands of frozen fruit juice concentrate are safe if they are reconstituted 
by the user with water from a safe source. Fruit juices that must be kept refrigerated from the time they are 
processed to the time of consumption might be either fresh (unpasteurized) or heat-treated (pasteurized); only juices 
labeled as pasteurized should be considered free of risk from Cryptosporidium. Other pasteurized beverages and 




1. Travel, particularly to developing countries, might result in significant risks for the exposure of HIV-
infected persons to opportunistic pathogens, especially for patients who are severely immunosuppressed. 
Consultation with health-care providers and/or with experts in travel medicine will help patients plan itineraries 
(BIII). 
2. During travel to developing countries, HIV-infected persons are at even higher risk for foodborne and 
waterborne infections than they are in the United States. Foods and beverages — in particular, raw fruits and 
vegetables, raw or undercooked seafood or meat, tap water, ice made with tap water, unpasteurized milk and dairy 
products, and items purchased from street vendors — might be contaminated (AII). Items that are generally safe 
include steaming hot foods, fruits that are peeled by the traveler, bottled (especially carbonated) beverages, hot 
coffee or tea, beer, wine, and water brought to a rolling boil for 1 minute (AII). Treating water with iodine or 
chlorine might not be as effective as boiling but can be used, perhaps in conjunction with filtration, when boiling is 
not practical (BIII). 
3. Waterborne infections might result from swallowing water during recreational activities. To reduce the 
risk for cryptosporidiosis and giardiasis, patients should avoid swallowing water during swimming and should not 
swim in water that might be contaminated (e.g., with sewage or animal waste) (BII). 
4. Antimicrobial prophylaxis for traveler’s diarrhea is not recommended routinely for HIV-infected persons 
traveling to developing countries (DIII). Such preventive therapy can have adverse effects and can promote the 
emergence of drug-resistant organisms. Nonetheless, several studies (none involving an HIV-infected population) 
have shown that prophylaxis can reduce the risk for diarrhea among travelers (CDC. Health information for 
international travel, 1999–2000. Atlanta, Georgia: U.S. Department of Health and Human Services, 1999:202). 
Under selected circumstances (e.g., those in which the risk for infection is very high and the period of travel brief), 
the provider and patient may weigh the potential risks and benefits and decide that anti-biotic prophylaxis is 
warranted (CIII). For those persons to whom prophylaxis is offered, fluoroquinolones (e.g., ciprofloxacin [500 mg 
daily]) can be considered (CIII), although fluoroquinolones should not be given to children or pregnant women. 
Trimethoprim-sulfamethoxazole (TMP-SMZ) (one double-strength tablet daily) also has been shown to be effective, 
but resistance to this drug is now common in tropical areas. Persons already taking TMP-SMZ for prophylaxis 
against Pneumocystis carinii pneumonia (PCP) might gain some protection against traveler’s diarrhea. For HIV-in-
fected persons who are not already taking TMP-SMZ, health-care providers should be cautious in prescribing this 
agent for prophylaxis of diarrhea because of the high rates of adverse reactions and the possible need for the agent 
for other purposes (e.g., PCP prophylaxis) in the future. 
5. All HIV-infected travelers to developing countries should carry a sufficient supply of an antimicrobial 
agent to be taken empirically should diarrhea develop (BIII). One appropriate regimen is 500 mg of ciprofloxacin 
twice a day for 3–7 days. Alternative antibiotics (e.g., TMP-SMZ) should be considered as empirical therapy for use 
by children and pregnant women (CIII). Travelers should consult a physician if their diarrhea is severe and does not 
respond to empirical therapy, if their stools contain blood, if, fever is accompanied by shaking chills, or if 
dehydration develops. Antiperistaltic agents (e.g., diphenoxylate and loperamide) are used for the treatment of 
diarrhea; however, they should not be used by patients with high fever or with blood in the stool, and their use 
should be discontinued if symptoms persist beyond 48 hours (AII). Antiperistaltic agents are not recommended for 
children (DIII). 
6. Travelers should be advised about other preventive measures appropriate for anticipated exposures (e.g., 
chemoprophylaxis for malaria, protection against arthropod vectors, treatment with immune globulin, and 
vaccination) (AII). They should avoid direct contact of the skin with soil or sand (e.g., by wearing shoes and 
protective clothing and using towels on beaches) in areas where fecal contamination of soil is likely (BIII). 
7. In general, live-virus vaccines should be avoided (EII). One exception is measles vaccine, which is 
recommended for nonimmune persons. However, measles vaccine is not recommended for persons who are severely 
immunosuppressed (DIII); immune globulin should be considered for measles-susceptible, severely 
immunosuppressed persons who are anticipating travel to measles-endemic countries (BIII). Another exception is 
varicella vaccine, which may be administered to asymptomatic nonimmunosuppressed children (BII). Inactivated 
(killed) poliovirus vaccine should be used instead of oral (live) poliovirus vaccine, which is contraindicated for HIV-
infected per-sons. Persons at risk for exposure to typhoid fever should be administered an inactivated parenteral 
typhoid vaccine instead of the live attenuated oral preparation. Yellow fever vaccine is a live-virus vaccine with 
uncertain safety and efficacy in HIV-infected persons. Travelers with asymptomatic HIV infection who cannot avoid 
potential exposure to yellow fever should be offered the choice of vaccination. If travel to a zone with yellow fever 
is necessary and vaccination is not administered, patients should be advised of the risk, instructed in methods for 
avoiding the bites of vector mosquitoes, and provided with a vaccination waiver letter. 
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8. In general, killed and recombinant vaccines (e.g., diphtheria-tetanus, rabies, hepatitis A, hepatitis B, 
Japanese encephalitis vaccines) should be used for HIV-infected persons just as they would be used for non-
HIV–infected persons anticipating travel (BIII). Preparation for travel should include a review and updating of 
routine vaccinations, including diphtheria-tetanus for adults and all routine immunizations for children. The 
currently available cholera vaccine is not recommended for persons following a usual tourist itinerary, even if travel 
includes countries reporting cases of cholera (DII). 
9. Travelers should be informed about other area-specific risks and instructed in ways to reduce those risks 
(BIII). Geographically focal infections that pose a high risk to HIV-infected persons include visceral leishmaniasis 
(a protozoan infection transmitted by the sandfly) and several fungal infections (e.g., Penicillium marneffei 
infection, coccidioidomycosis, and histoplasmosis). Many tropical and developing areas have high rates of 
tuberculosis. 
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